

論文

平成22年(2010年)

Tanaka Y.

Achieving drug-free remission: elucidating the role of TNF in rheumatoid arthritis.

Int J Clin Rheumatol 5, 391–393, 2010

Shimizu S, Osada Y, Kanazawa T, Tanaka Y, Arai M.

Suppressive effect of azithromycin on Plasmodium berghei mosquito stage development and apicoplast replication.

Malaria J 9, 73–81, 2010

Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, Tanaka Y.

A calcineurin inhibitor, tacrolimus overcomes treatment-unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.

J Rheumatol 37, 512–520, 2010

Ikenouchi-Sugita A, Yoshimura R, Kishi T, Umene-Nakano W, Katsuki A, Saito K, Iwata H, Tanaka Y, Nakamura J.

No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients.

World J Biol Psychiatry 11, 121–128, 2010

Tsujimura S, Saito K, Nakayamada S, Tanaka Y.

Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis.

Mod Rheumatol 20, 139–146, 2010

Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, Tanaka Y.

Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling.

Arthritis Rheum 62, 952–959, 2010

Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y.

Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway.

Biochem Biophys Res Commun 394, 317–322, 2010

Higashi T, Hashimoto K, Takagi R, Mizuno Y, Okazaki Y, Tanaka Y, Matsushita S

Curdlan induces DC-mediated Th17 polarization via jagged1 activation in human dendritic cells.

Allergology In 59, 161–166, 2010

Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T.
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR
(remission induction by remicade in RA) study.

Ann Rheum Dis 69, 1286–1291, 2010

Kurihara R, Yamaoka K, Sawamukai N, Shimajiri S, Oshita K, Yukawa S, Tokunaga M, Iwata S, Saito K,
Sasaguri Y, Tanaka Y.

C5a promotes migration, proliferation, and vessel-formation in endothelial cells.

Inflamm Res 59, 659–666, 2010

Choo Q-Y, Ho PC, Tanaka Y, Lin H-S.

Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed
lipopolysaccharide-stimulated NF-κB p65 nuclear accumulation in human rheumatoid arthritis synovial
fibroblastic E11 cells.

Rheumatology 49, 1447–1460, 2010

Kameda H, Ueki Y, Saito K, Nagaoka s, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y,
Takeuchi T.

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active
rheumatoid arthritis despite MTX therapy: A randomized trial.

Mod Rheumatol 20, 531–538, 2010

森博子、岡田洋右、田中良哉

2型糖尿病合併高コレステロール血症患者におけるアトルバスタチンとロスバスタチンの血清脂質に及ぼす
影響の比較検討

Therapeutic Research 31, 709–714, 2010

新生忠司、岡田洋右、田中良哉

2型糖尿病患者におけるピオグリタゾン追加による尿中微量アルブミン減少効果の検討

Pharma Medica 28, 125–132, 2010

Tanaka Y.

Achieving drug-free remission: elucidating the role of TNF in rheumatoid arthritis

Int J Clin Rheumatol (2010) 5, 391–393

田中良哉

糖尿病と免疫機能

プラクティス(2010)27, 36–41

田中良哉、鈴木克典、齋藤和義
関節リウマチにおける生物学的製剤による治療の新展開と結核の発症
Kekkaku(2010)85, 34-37

田中良哉
ステロイド骨粗鬆症のリスクマネジメント
日本医師会雑誌(2010)138, 2304-2305

田中良哉
関節リウマチに対する抗 CD20 抗体オクレリズマブの抗リウマチ効果
リウマチ科(2010)43, 68-75

岩田慈、山岡邦宏、田中良哉
Syk キナーゼインヒビターの抗リウマチ効果
リウマチ科(2010)43, 51-56

田中良哉
免疫抑制薬の使い方
臨床研修プラクティス(2010)7 (3) 26-28

田中良哉
関節リウマチの薬
流(2010)271, 5-19

田中良哉
序 ～低分子抗炎症薬は生物学的製剤を超えるか？～
炎症と免疫(2009)17, 516-517

田中良哉
抗体製剤を中心とする生物学的製剤の構造とその特徴
治療学(2010)44, 167-171

田中良哉
関節リウマチで薬剤フリーとなった症例
治療学(2010)44, 227-231

田中良哉
免疫難病の治療と臨床的課題 ～生物学的製剤による関節リウマチ治療のパラダイムシフトを中心に～
実験医学(2010)28, 615-620

辻村静代、田中良哉

難治性関節リウマチ患者末梢血リンパ球におけるP糖蛋白質を指標とした治療戦略
リウマチ科(2010)43, 199-204

田中良哉

関節リウマチ治療の最終ゴール： 真の寛解とは？

Pharma Medica(2010)28 (3) 9-14

山岡邦宏、齋藤和義、田中良哉.

JAK阻害薬

Pharma Medica(2010)28 (3) 63-66

田中良哉

リウマチの薬物療法

RAナーシング(2010)2, 6-13

田中良哉

関節リウマチと骨粗鬆症

総合臨床(2010)59, 558-563

田中良哉

抗体医薬～B細胞標的治療の進歩～

Renal Transplantation(2010)10 (3), 2-5

岩田慈、齋藤和義、徳永美貴子、田中良哉

生物学的製剤による治療の可能性

リウマチ科(2010)43, 279-284

山岡邦宏、田中良哉

低分子化合物による関節リウマチの治療(Jak阻害薬とSyk阻害薬)

九州リウマチ(2010)30, 7-11

田中良哉

関節リウマチ患者の骨治療

Clinical Calcium(2010)20, 735-742

山岡邦宏、田中良哉

低分子化合物による関節リウマチの治療

九州リウマチ(2010)30, 7-11

田中良哉

関節リウマチ～バイオフリー寛解へのアプローチ～

Medicament News(2010) 2013, 4-6

田中良哉

B細胞標的療法

最新医学(2010) 65, 1037-1044

湯川宗之助、山岡邦宏、澤向範文、島尻正平、齋藤和義、田中良哉

強皮症病態におけるマスト細胞の関与～マスト細胞を標的とした治療の可能性

日本臨床免疫学会雑誌(2010) 33, 81-86

齋藤和義、田中良哉.

関節リウマチに対するTNF阻害薬の長期治療成績

リウマチ科(2010) 43, 327-336

田中良哉

SLEの臨床試験の問題点

リウマチ科(2010) 43, 434-440

齋藤和義、田中良哉

B細胞を標的とした治療(リツキシマブ、エプラツズマブ、ベリムマブ)

炎症と免疫(2010) 18, 275-279

竹内勤、田中良哉、木村友厚、田中栄、三森経世

関節リウマチ治療における生物学的製剤～現在から未来～～

Pharma Medica (2010) 28, 189-196

中野和久、田中良哉

ドパミンによるTh17細胞の誘導

臨床免疫・アレルギー科(2010) 53, 527-534

岡田洋右、田中良哉

ステロイド骨粗鬆症の病態と治療

リウマチ科 (2010) 43, 485-490

竹内勤、田中良哉、小嶋俊久、亀田秀人.

RAの治療ゴール

Athritis (2010) 8, 37-47

田中良哉
抗リウマチ薬
今日の健康 (2010) 115-121

山岡邦宏、田中良哉。
サイトカインシグナル阻害薬の現状
臨床検査(2010) 54, 677-681

田中良哉
RRR 研究から検証する
医学のあゆみ(2010) 234, 101-105

斎藤和義、田中良哉
治療戦略の検証: BeSt スタディ、COMET スタディから得られたもの
医学のあゆみ(2010) 234, 24-39

田中良哉
関節リウマチ
臨床と研究(2010) 87, 899-902

名和田雅夫、斎藤和義、田中良哉
関節リウマチにおける真の寛解(薬剤フリー寛解)とは?
分子リウマチ治療(2010) 3, 128-132

山岡邦宏、前岡圭佑、田中良哉
JAK 阻害薬: 抗リウマチ作用と作用機序
実験医学(2010) 28, 2041-2043

田中良哉、山岡邦宏
サイトカイン・シグナル伝達阻害薬 ~Jak 阻害薬~
Medical Science Digest (2010) 36, 964-967

田中良哉、山岡邦弘
新規低分子抗リウマチ薬
Modern Physician (2010) 30, 1061-1064

田中良哉
生物学的製剤の登場によりリウマチ治療はどう変わっているか: 生物学的製剤を中心に
リウマチクリニック(2010) 12, 8-9

中野和久、松下祥、田中良哉
ヒト Th17 細胞の動態と治療薬による修飾
Frontiers in Rheumatology & Clinical Immunology (2010) 4, 150–154

山岡邦宏、田中良哉
RA とサイトカインシグナル伝達：シグナル伝達阻害効果
Frontiers in Rheumatology & Clinical Immunology (2010) 4, 167–174

田中良哉
エタネルセプトをいかに用いるか
メディカル朝日 (2010) 39 (9), 34–35

田中良哉
TNF 阻害薬 1 剤目が効果不十分な RA 症例の治療戦略
リウマチ科 (2010) 44, 231–237

田中良哉
関節リウマチ
臨床と研究 (2010) 87, 1196–1201

田中良哉
関節リウマチ治療薬による骨代謝の改善
腎と骨代謝 (2010) 23, 299–307

山岡邦宏、田中良哉
分子標的薬
カレントテラピー (2010) 28, 968–969

田中良哉
膠原病肺
カレントテラピー (2010) 28, 969–970

田中良哉
骨・関節疾患の抗サイトカイン療法
Clinical Calcium (2010) 20, 1545–1552

田中良哉
膠原病に於ける感染症
診断と治療 (2010) 98, 1698–1704

山岡邦弘、田中良哉
関節リウマチにおける樹状細胞
リウマチ科 (2010) 44, 376–380

田中良哉、針谷正祥、三森明夫、越智小枝、岸本暢将
関節炎の鑑別：診断と治療の進歩
日本内科学会雑誌 (2010) 99, 2503–2520

田中良哉
関節リウマチにおけるB細胞標的療法
Medical Science Digest (2010) 36, 1103–1105

田中良哉
TNF阻害薬
治療学 (2010) 44, 1097–1102

山岡邦弘、田中良哉
JAK阻害薬
治療学 (2010) 44, 1138–1141

山岡邦弘、田中良哉
関節リウマチ治療におけるJAK阻害薬の可能性を探る
分子リウマチ治療 (2010) 3, 183–185

田中良哉
ベリムマブとアタシセプト
炎症と免疫 (2010) 18, 601–607

岡田洋右、森博子、橋本修、田中良哉
ビスホスホネートの位置づけ
Clinical Calcium (2010) 20, 1711–1717

山岡邦弘、田中良哉
シグナル伝達標的低分子化合物による疾患制御
最新医学 (2010) 65, 2424–2429

田中良哉
慢性炎症と疾患：序論
最新医学 (2010) 65, 2327–2328

田中良哉

関節リウマチにおける生物学的製剤治療に伴う結核

関節外科(2010) 29, 1429–1434

岡田洋右、飯田武、田中良哉

ステロイド性大腿骨頭壊死症のメカニズム

リウマチ科(2010) 44, 413–417

岩田慈、山岡邦弘、齋藤和義、田中良哉

SLE に対する B 細胞を標的とした治療 ~rituximab, belimumab, atacicept~

リウマチ科(2010) 44, 453–457

齋藤和義、田中良哉

寛解を目指した薬物療法の実際

Medical Practice (2010) 27, 2090–2094

齋藤和義、田中良哉

新たな SLE 治療反応基準

リウマチ科 (2010) 44, 585–595

徳永美貴子、齋藤和義、田中良哉

SLE におけるベリムマブ(抗 BAFF 抗体)の臨床的有効性

リウマチ科 (2010) 44, 596–600

田中良哉

生物学的製剤は何を使いますか

Arthritis (2010) 8, 205–212

田中良哉

T 細胞選択的共刺激調節剤の新しい作用機序とその臨床的特性について

RA Trends (2010) 1, 2–5

田中良哉

バイオフリー寛解を目指した関節リウマチ治療 ~RRR スタディなどから~

臨床リウマチ(2010)22, 401–405

田中良哉

関節リウマチにおける生物学的製剤治療に伴う結核

関節外科(2010)29, 1429–1434

森博子、岡田洋右、新生忠司、西田啓子、田中良哉

著明なインスリン抵抗性を呈した polycystic ovary syndrome に対し生活習慣指導と少量のビグアナイドが奏功した 1 例

Diabetes J (2010) 38, 69–73

宮川一平、齋藤和義、花見健太郎、名和田雅夫、湯川宗之助、山岡邦宏、中野和久、平田信太郎、福興俊介、田中良哉

抗 IL-6 受容体抗体 tocilizumab が著効した二次性アミロイドーシス合併関節リウマチの 1 例

日本内科学会雑誌(2010)99, 160–162

新生忠司、岡田洋右、杉澤千穂、広瀬暁子、西田啓子、田中良哉

躁状態に伴う生活習慣の変化により著明な血糖コントロール増悪をきたした 2 型糖尿病の 2 例

Diabetes Frontier (2010) 21, 593–598

新生忠司、岡田洋右、吉村暁子、西田啓子、田中良哉

成人発症 nesidioblastosis による難治性低血糖症に対してジアゾキサイドが長期にわたり有効であった 1 例

糖尿病 (2010) 53, 803–809

平成23年(2011年)

Tanaka Y, Yamaoka K.

Cytokine-mediated signals as targets for treatment of rheumatoid arthritis: a JAK inhibitor in vitro and in vivo.

Int J Clin Rheumatol 6, 439–444, 2011

Tanaka Y, Iwata S, Yamaoka K.

Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases.

Inflammation and Regeneration 31, 237–244, 2011

Tanaka Y, Miyasaka N.

Recent progress in small molecular production for the treatment of joint and bone diseases: an over view.

Inflammation and Regeneration 31, 341–343, 2011

Tanaka Y.

Denosumab for the treatment of joint and bone diseases.

Inflammation and Regeneration 31, 344–348, 2011

Yamaoka K, Kubo S, Sonomoto K, Maeshima K, Tanaka Y.

JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug.

Inflammation and Regeneration 31, 349–353, 2011

Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T.

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

Mod Rheumatol 21, 122–133, 2011

Yamaoka K, Tanaka Y.

Janus kinase (JAK) inhibitors in rheumatoid arthritis.

Curr Rheumatol Rev 306–312, 2011

Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Hanami K, Tanaka Y.

Efficacy of combination therapy of anti-TNF- α antibody infliximab and methotrexate in refractory entero-Behcet's disease.

Mod Rheumatol 21, 184–191, 2011

Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, Hanami K, Fukuyo S, Miyagawa I, Kubo S, Tanaka Y.

Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.

J Rheumatol 38, 633–641, 2011

Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naïve T-cells and a D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model.

J Immunol 186, 3745–3752, 2011

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Toma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H Hashimoto A, Koike t, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M.

Incidence and risk factors for serious infection in rheumatoid arthritis patients treated with tumor necrosis factor (TNF) inhibitors; a report from the registry of Japanese Rheumatoid Arthritis Patients for Long-Term Safety (REAL).

J Rheumatol 38, 1258–1264, 2011

Oshita K, Yamaoka K, Udagawa N, Fukuyo S, Sonomoto K, Maeshima K, Kurihara R, Nakano K, Saito K, Okada Y, Chiba K, Tanaka Y.

Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production.

Arthritis Rheum 63, 1658–1667, 2011

Morotomi N, Fukuda K, Nakano M, Ichihara S, Oono T, Yamazaki T, Kobayashi N, Suzuki T, Tanaka Y, Taniguchi H.

Evaluation of intestinal microbiotas of healthy Japanese adults and effect of antibiotics using the 16S ribosomal RNA gene based clone library method.

Biol Pharm Bull 34, 1101–1020, 2011

Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Twillich S.

Phase 2 study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate.

Arthritis Care Res 63, 1150–1158, 2011

Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nakajima A, Atsumi T, Yasuda S, Tanaka Y, Saito K, Tohma S, Fujii T, Ihata A, Tamura N, Kawakami A, Sugihara T, Ito S, Miyasaka N, Harigai M for the REAL Study Group.

The REAL database reveals no significant risk for serious infection during treatment with methotrexate over 8 mg/week in patients with rheumatoid arthritis.

Mod Rheumatol 21, 444–448, 2011

Kameda H, Kanbe K, Sato e, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa s, Tanaka Y, Yamanaka H, Takeuchi T.

Continuation of Methotrexate (MTX) Resulted in Better Clinical and Radiographic Outcomes than Its Discontinuation upon Commencing Etanercept in Patients with Rheumatoid Arthritis: 52-Week Results from the JESMR Study.

J Rheumatol 38, 1585–1592, 2011

Koike T, Harigai M, Inokuma s, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M.

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis.

Mod Rheumatol 21, 343–351, 2011

Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N.

Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial.

Mod Rheumatol 21, 458–468, 2011

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H.

Postmarketing Surveillance of Tocilizumab for Rheumatoid Arthritis in Japan — Interim Analysis of 3,881 Patients.

Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H.

Clinical, radiographic, and functional effectiveness of tocilizumab for rheumatoid arthritis patients – REACTION 52-week study –

Rheumatology 50, 1908–1915, 2011

Tanaka Y, Yamaoka K.

Cytokine-mediated signals as targets for treatment of rheumatoid arthritis: a JAK inhibitor in vitro and in vivo

Int J Clin Rheumatol 6, 439–444, 2011

今永たか子、佐伯覚、舌間秀雄、上中香代子、深川直美、大谷美由紀、中村利孝、田中良哉

当院におけるベルト式ヒッププロテクターの導入の評価:院内転倒による大腿骨頸部骨折の減少に向けて

Osteoporosis Japan 19, 236–239, 2011

森博子、岡田洋右、吉村暁子、新生忠司、西田啓子、田中良哉

2型糖尿病におけるビオグリタゾン追加投与によるインスリン分泌促進薬減量の有効性と安全性

糖尿病 54, 786–794, 2011

岡田洋右、成澤学、森博子、田中良哉

食後高血糖是正の重要性: CGM を用いた評価と DPP-4 阻害薬の有用性

新薬と臨床(2011)60, 72–77

齋藤和義、田中良哉

関節リウマチの薬物療法下における感染症対策は

分子リウマチ治療(2011)4, 1–4

田中良哉

CD20 と CD22

最新医学(2011)66, 244–251

山岡邦弘、田中良哉

JAK

最新医学(2011)66, 279–286

中山寿、田中良哉、竹内勤

日常診療におけるトリズマブの有効性と安全性の検証(REACTION 試験)

Frontiers in Rheumatology & Clinical Immunology(2011) 5, 38–44

中野和久、田中良哉
ドパミン産生樹状細胞による Th17 細胞の誘導
臨床免疫・アレルギー科(2011)55, 247-254

西田啓子、岡田洋右、田中良哉
関節リウマチにおけるインスリン抵抗性とレプチン
リウマチ科 (2011) 45, 76-80

中野和久、田中良哉
生物学的製剤の副作用とその対策
内科 (2011) 107, 679-685

田中良哉
新規抗リウマチ薬
Bone Joint Nerve (2011) 1, 134-139

田中良哉
サイトカインの最近の知見について
日本医事新報(2010)4518, 76-77

田中良哉
B 細胞を標的とした関節リウマチの制御
整形・災害外科(2011)54, 320-321

齋藤和義、田中良哉
アバタセプトの関節リウマチ治療における位置づけ
九州リウマチ(2011)31, 1-6

山岡邦宏、田中良哉
JAK 阻害薬
九州リウマチ(2011)31, 7-11

田中良哉
SLE の抗 B 細胞療法の進歩
リウマチ科(2011)45, 277-284

田中良哉
新規抗リウマチ薬が骨に及ぼす効果
Osteoporosis Japan (2011) 19, 167-172

田中良哉
全身性エリテマトーデスの B 細胞標的治療
産業医科大学雑誌(2011)33, 173-191

田中良哉
B 細胞を標的とした抗体療法
THE BONE(2011) 25, 135-140

竹内勤、田中良哉、山中寿、針谷正祥
関節リウマチにおける Treat to Target
Arthritis(2011) 9, 74-79

田中良哉
なぜ今 X 線撮影が重要なのか?
Arthritis(2011) 9, 80-81

田中良哉
膠原病の治療指針と治療に伴う合併症の予防と治療
Medical Practice(2011) 28, 1160-1168

徳永美貴子、齋藤和義、田中良哉
関節リウマチ患者の関節外症状に生物学的製剤は有効か?
内科 (2011) 107, 1417-1422

澤向範文、湯川宗乃助、田中良哉
マスト細胞の補体による活性化
臨床免疫・アレルギー科(2011) 55, 608-611

齋藤和義、岩田慈、田中良哉
関節リウマチに対する脾臓チロシンキナーゼ阻害剤の効果
リウマチ科(2011) 45, 572-577

田中良哉
関節リウマチ診療のパラダイムシフト
日本内科学会雑誌(2011) 100, 1978-1986

田中良哉
抗 RANKL 抗体による関節リウマチの治療
CLINICAL CALCIUM(2011) 21, 1223-1229

田中良哉

SLE における間葉系幹細胞移植について

リウマチ科(2011)46, 72-77

山岡邦宏、田中良哉

Janus kinase (JAK) 特異的阻害薬の効果に基づく作用機序の検討

リウマチ科(2011)46, 84-88

田中良哉

関節リウマチに対する B 細胞標的治療

医学のあゆみ(2011)238, 665-670

齋藤和義、田中良哉

インフリキシマブによる臨床的寛解導入と中止の維持

Orthopaedics(2011)24 (9), 13-19

辻村静代、田中良哉

全身性自己免疫疾患におけるグルココルチコイド抵抗性のメカニズム

リウマチ科(2011)46, 197-202

齋藤和義、田中良哉

B細胞に対する生物学的製剤

日本内科学会雑誌(2011)100, 2991-2997

田中良哉

SLE の最新治療

Frontiers in Rheumatology & Clinical Immunology(2011) 5, 226-230

田中良哉

膠原病・関節リウマチ性疾患における骨代謝異常

Medical Science Digest(2011)37, 578-561

岡田洋右、西田啓子、田中良哉

関節リウマチの動脈硬化に対する生物学的製剤の作用

リウマチ科(2011)46, 309-314

田中良哉

関節リウマチにおけるアディポカインの役割

リウマチ科(2011)46, 564-569

岩田慈、齋藤和義、徳永美貴子、田中良哉

シェーグレン症候群に対するリツキシマブ治療後のB細胞再構築とヘルパーT細胞バランス
リウマチ科(2011)46, 528-532

田中良哉、竹内勤、山中寿、針谷正祥、宮坂信之
2010年関節リウマチ新分類基準とその臨床応用
臨床リウマチ(2011)23, 339-343

岡田洋右、橋本修、田中良哉
ビスホスフォネート
腎と透析(2011)71, 873-877

Kubo S, Yamaoaka K, Saito K, Nakano K, Sawamukai N, Hirata S, Hanami K, Fukuyo S, Miyagawa I, Tanaka Y.

Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis.
Joint Bone Spine (2011) 78, 99-100

Hiura M, Abe S, Tabaru A, Shimajiri S, Hanami K, Saito K, Tanaka Y, Harada M.
A case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis.
Hepatol Res (2011) 41, 492-496

Kubo S, Saito K, Yamaoaka K, Iwata S, Hanami K, Fukuyo S, Miyagawa I, Tanaka Y.
Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis.
Joint Bone Spine (2011) 78, 535-536

山本直、岡田洋右、新生忠司、西田啓子、田中良哉
ソフトドリンクケトアシドーシスに高トリグリセライド血症と重症急性胰炎を合併した1例
糖尿病 (2011) 5, 34-39

新生忠司、岡田洋右、山本直、吉村暁子、西田啓子、田中良哉
脾切除後の難治性低血糖にジアゾキサイドが著効した脾頭過形成の1例
Diabetes J (2011) 39, 21-27

森博子、岡田洋右、廣瀬暁子、西田啓子、森田恵美子、田中良哉
アログリプチンとボグリボースの併用効果を持続血糖モニターで確認できた1例
糖尿病 (2011) 54, 425-429

鳥本桂一、岡田洋右、西田啓子、山本直、田中良哉
高度の低カリウム血症により歩行困難となった高齢者の1例

平成24年(2012年)

Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, Bingham III CO, Ashrafzadeh A, Travers H, Safa-Leathers S, Kumar S, Dummer W. Efficacy and safety of ocrelizumab in patients with active rheumatoid arthritis with an inadequate response to at least one TNF inhibitor: results from the phase III SCRIPT trial.

Arthritis Rheum 64, 360–370, 2012

Umeshara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H.

Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.

Mod Rheumatol 22, 21–30, 2012

Harigai M, Tanaka Y, Maisawa S; on behalf of the JA21963 study group.

Safety and efficacy of various dosages of ocrelizumab in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate therapy: a placebo-controlled, double-blind, parallel-group study.

J Rheumatol 39, 486–495, 2012

Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saito K, Kamachi M, Kawaguchi Y, Ikari K, Mohammed O W, Matsuda K, Terao C, Ohmura K, Myouzen K, Hosono N, Tsunoda T, Nishimoto N, Mimori T, Matsuda F, Tanaka Y, Sumida T, Yamanaka H, Takasaki Y, Koike T, Horiuchi T, Hayashi K, Kubo M, Kamatani N, Yamada R, Nakamura Y, Yamamoto K.

A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus erythematosus in Japanese.

PLoS Genet. 8, e1002455–1–10, 2012

Tanaka Y, Yamanaka H, Saito K, Iwata S, Miyagawa I, Seto Y, Momohara S, Nagasawa H, Kameda H, Kaneko Y, Izumi K, Amano K, Takeuchi T.

Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept

Mod Rheumatol 22, 186–194, 2012

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Mitasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D and the GO-FORTH study group.

Golimumab, a human anti-TNF- α monoclonal antibody, injected subcutaneously every 4 weeks in Japanese patients with active rheumatoid arthritis in combination with methotrexate: results of the Phase 2/3,

multicenter, randomized, double-blind, placebo-controlled GO-FORTH study through 24 weeks.

Ann Rheum Dis 71, 817–824, 2012

Oki H, Aoki T, Saito K, Yamashita Y, Hanamiya M, Hayashida Y, Tanaka Y, Korogi Y.

Thin-section chest CT findings in systemic lupus erythematosus with antiphospholipid syndrome: A comparison with systemic lupus erythematosus without antiphospholipid syndrome.

Eur J Radiol 81, 1335–1339, 2012

Iwata S, Yamaoka K, Niilo H, Nakano K, Wang S-P, Akashi K, Tanaka Y.

Amplification of toll-like receptor-mediated signaling through Syk in human B cell activation.

J Allergy Clin Immunol 129, 1594–1601, 2012

Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Saito K, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H.

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: Retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).

Mod Rheumatol 22, 327–338, 2012

Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishi K, Yoshimatsu H, Tanaka Y.

A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN- γ and IL-17 production by human CD4+ T cells.

Arthritis Rheum 64, 1790–1798, 2012

Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, Ihata A, Ishigatubo Y, Saito K, Tanaka Y, Ito S, Sumida T, Tohma S, Tamura N, Fujii T, Sugihara T, Kawakami A, Hagino N, Ueki Y, Hashiramoto A, Nagasaka K, Miyasaka N, Harigai M, for the REAL Study Group.

Time-dependent increased risk for serious infection from continuous use of TNF antagonists during three years in rheumatoid arthritis patients.

Arthritis Care Res 64: 1125–1134, 2012

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M.

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.

Rheumatol Int 32: 1617–24, 2012

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M.

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis.

Rheumatol Int 32: 1511–9, 2012

Sawamukai N, Satake A, Schmidt AM, Lamborn IT, Tanaka Y, Kambayashi T.

Cell autonomous role of TGF β and IL-2 receptor in CD4+ and CD8+ inducible regulatory T cell generation during graft-versus-host disease.

Blood 119: 5575–83, 2012

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y.

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.

Mod Rheumatol 22, 498–508, 2012

Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y; Additional Members of the GB-0998 Study Group. Additional Members of the GB-0998 Study Group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial.

Mod Rheumatol 22, 382–393, 2012

Mori H, Okada Y, Arao T, Nishida K, Tanaka, Y.

Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.

Adv Ther 29, 635–644, 2012

Iwata S, Saito K, Tokunaga M, Tanaka Y.

B-cell or T-cell-dominant recurrence after rituximab therapy in patients with SLE.

Ann Rheum Dis 71, 1749–1750, 2012

Ikenouchi-Sugita A, Yoshimura R, Kishi T, Umene-Nakano W, Hori H, Katsuki A, Saito K, Iwata N, Tanaka T, Nakamura J.

No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients.

Hum Psychopharm Clin 26, 348–351, 2012

Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatubo Ym Atzumi T, Koike T, Nakaji A, Tmura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M.

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anti-cytokine therapy with different target molecules.

Ann Rheum Dis 71, 1820–1826, 2012

Sonomoto K, Yamaoka K, Oshita K, Fukuyo S, Zhang X, Nakano K, Okada Y, Tanaka Y.

IL-1 β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt5a/Ror2 pathway.

Arthritis Rheum 64, 3353–3363, 2012

Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, Miyasaka N. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity.

Mod Rheumatol 22, 814–823, 2012

Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Skai F, Sugiyama H, Matsushima H, Kojima T, Ohta S, Ishibe Y, Sawabe T, Ota Y, Ishii K, Miyazono H, Nonomura Y, Saito K, Tanaka Y, Nagasawa H, Takeuchi T, Nakajima A, Ohtubo H, Ohnishi, Goto Y, Dobashi H, Miyasaka N, Harigai M.

Pneumocystis pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of fifteen cases and analysis of risk factors.

Mod Rheumatol 22, 849–858, 2012

Umeshara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki H, Azumi A, Kojima M, Nakamura S, Inoue D, Zen Y, all Japan IgG4-related disease working group.

A Novel Clinical Entity, IgG4-Related Disease (IgG4RD) – General Concept and Detail-

Mod Rheumatol (2012) 22, 1–14

Tanaka Y.

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.

Curr Opin Rheumatol (2012) 24, 319–326

Tanaka Y, Maeshima Y, Yamaoka K.

In vitro and in vivo analysis of a Jak inhibitor in rheumatoid arthritis.

Ann Rheum Dis (2012) 71, i70–i74

Tsujimura S, Tanaka Y.

Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease

Clin Exp Nephrol (2012) 16, 102–108

森博子、岡田洋右、田中良哉

ピオグリタゾンの骨代謝・骨質に及ぼす影響についての検討

Osteoporosis Japan 20, 13–17, 2012

新生忠司、岡田洋右、鳥本桂一、山本直、田中良哉

当科における甲状腺クリーゼ 8 症例の臨床的検討

内科 109, 519–523, 2012

平田信太郎、齋藤和義、澤向範史、中野和久、山岡邦宏、田中良哉

関節リウマチ患者における COX-2 選択的阻害薬セレコキシブの上部消化管自覚症状に対する影響

～非ステロイド性抗炎症薬(NSAIDs)切り替え効果の検討～

九州リウマチ 32, 17–25, 2012

岡田洋右、森博子、名和田雅夫、齋藤和義、渥美達也、中山久徳、當間重人、川人豊、山西裕司、長谷川均、谷村一秀、根来伸夫、植木幸孝、川上純、江口勝美、田中良哉

関節リウマチ・ステロイド骨粗鬆症に於ける早期治療介入の重要性：当科およびEDITOR-J の解析より

Osteoporosis Japan 20, 412–415, 2012

森博子、岡田洋右、田中良哉

女性におけるビタミン D と生活習慣病の関係

産業医科大学雑誌 34, 323–329, 2012

田中良哉

Jak 阻害薬－生物学的製剤を超えられるか？

Mebio(2012)29, 96–101

田中良哉

全身性エリテマトーデス

アレルギー・免疫(2012)19, 64–72

田中良哉

関節リウマチ治療の最近の進歩(overview)

Clinical Calcium(2012) 22, 169–178

齋藤和義、田中良哉

関節リウマチ

日本医師会雑誌(2012) 140, 2296–2299

田中良哉

知っておきたい生物学的製剤の基礎知識

治療(2012) 94, 234–239

齋藤和義、田中良哉

インフリキシマブ-RAに対する現状と使用法の工夫

リウマチ科(2012) 47, 1-8

山中寿、田中良哉、川上純

進化する関節リウマチの診断と治療

最新医学(2012)67, 175-185

田中良哉、平田信太郎、齋藤和義

生物学的製剤中止のタイミング

最新医学(2012)67, 237-243

名和田雅夫、齋藤和義、田中良哉

生物学的製剤の使い分け

最新医学(2012) 67, 252-258

田中良哉

炎症性疾患におけるキナーゼ阻害薬の進歩:はじめに

医学のあゆみ(2012) 240, 555

山岡邦宏、前島圭祐、久保智史、園本格士朗、田中良哉

JAK 阻害薬 tofacitinib の抗リウマチ作用

医学のあゆみ(2012) 240, 562-566

平田信太郎、田中良哉

関節 X 線スコアリング - van der Heijde modified Sharp score の実際

Frontiers in Rheumatology & Clinical Immunology(2012) 6, 4-7

田中良哉、竹内勤、天野宏一、山中寿

HARMONY: アダリムマブを用いた関節リウマチ治療の多施設後ろ向き研究

Frontiers in Rheumatology & Clinical Immunology(2012) 6, 30-35

岩田慈、山岡邦宏、新納宏昭、中野和久、Sheau-Pey Wang、齋藤和義、赤司浩一、田中良哉

全身性自己免疫疾患における Syk の関与とその作用メカニズム

日本臨床免疫学会会誌(2012) 35, 56-61

山岡邦宏、前島圭祐、久保智史、田中良哉

樹状細胞における JAK3-Stat6 経路制御を介した炎症調節機構

日本臨床免疫学会会誌(2012) 35, 62-68

中野和久、花見健太郎、田中良哉

ドパミン受容体と自己免疫
リウマチ科(2012) 47, 189–194

田中良哉
炎症性免疫疾患に作用する分子標的薬
Medical Science Digest (2012) 38, 162–165

田中良哉
開発中の新薬
からだの科学(2012) 273, 69–73

田中良哉
生物学的製剤による関節リウマチ治療
CLINIC magazine (2012) 514, 27–33

山岡邦宏、前島圭祐、田中良哉
Janus Kinase (JAK) 阻害薬 tofacitinib の作用機序と自己免疫疾患治療薬としての可能性
リウマチ科(2012) 47, 97–100

山岡邦宏、前島圭祐、久保智史、田中良哉
樹状細胞における JAK3–Stat6 を介した炎症調節機構
臨床免疫・アレルギー科(2012) 57, 264–268

平田信太郎、田中良哉
専門医に紹介するタイミングとは?
内科(2012) 109, 615–620

前島圭祐、石井宏治、山岡邦宏、田中良哉
JAK 阻害薬の有効性は?
内科(2012) 109, 664–668

田中良哉
関節リウマチのプラクティス ～診断と治療の最新情報～
日本内科学会雑誌(2012) 101, 694–700

田中良哉
低分子抗炎症薬の進歩
炎症と免疫(2012) 20, 250–251

山岡邦宏、田中良哉

JAK3 の発見から臨床応用まで

炎症と免疫(2012) 20, 268-271

田中良哉

炎症と骨代謝

The BONE (2012) 26, 167-172

山岡邦宏、前島圭祐、久保智史、園本格子朗、田中良哉

JAK 阻害薬の抗リウマチ作用

日本臨床免疫学会雑誌(2012) 35, 112-117

田中良哉

生物学的製剤の新たな展開

Rheumatology Clinical Research (2012) 1, 8-9

山岡邦宏、田中良哉.

JAK-Staats シグナル伝達経路を介した IL-10 の產生制御

臨床免疫・アレルギー科(2012) 57, 470-474

田中良哉

関節リウマチ患者に於いて生物学的製剤使用時の細菌性肺炎発症は制御できるか？

Medical Practice (2012) 29, 1046

岩田慈、山岡邦宏、田中良哉

ヒト B 細胞活性化における Syk を介した TLR9 シグナルの増幅メカニズム

臨床免疫・アレルギー科(2012) 57, 513-517

山岡邦宏、田中良哉

JAK 阻害薬

医薬ジャーナル(2012) 48, 1527-1530

田中良哉

十分量 MTX と生物学的製剤の併用

炎症と免疫(2012) 20, 374-379

田中良哉

膠原病における生物学的製剤の使用と問題点

腎臓(2012) 35, 18-26

森博子、岡田洋右、橋本修、田中良哉

CKD-MBD のビスホスホネート治療
Clinical Calcium (2012) 22, 1034-1042

平田信太郎、山岡邦宏、田中良哉
どのように生物学的製剤を使うか: BeSt & RRR
分子リウマチ治療 (2012) 5, 131-134

田中良哉
次世代抗リウマチ薬として期待される Jak 阻害薬
MEDICAL NEWS (2012) 3, 8-13

田中良哉
T2T リコメンデーション
リウマチ科 (2012) 48, 19-25

尾下浩一、山岡邦宏、田中良哉
ヒト間葉系幹細胞による破骨細胞の活性制御
リウマチ科 (2012) 48, 103-108

山岡邦宏、久保智史、園本格士朗、前島圭祐、田中良哉
関節リウマチに対するトファシチニブ (CP-690,550) の効果
リウマチ科 (2012) 48, 109-114

田中良哉
リウマチ治療の現在・未来: 薬物療法
流 (2012) 290, 14-27

田中良哉、竹内勤、天野宏一、山中寿
国内エビデンスに見るトリズマブの有効性 (REACTION)
Frontiers in Rheumatology and Clinical Immunology (2012) 6, 132-136

田中良哉
TNF と RANKL を標的とした関節リウマチの治療
医学のあゆみ (2012) 242, 758-763

森博子、岡田洋右、田中良哉
糖尿病に於ける骨・血管連関
Clinical Calcium (2012) 22, 1343-1351

田中良哉

サイトカインを標的とした自己免疫疾患治療へのアプローチ：関節リウマチの治療革命
奈良県医師会医学会年報(2012)25, 88-92

田中良哉
関節リウマチの治療戦略 update
整形・災害外科(2012) 55, 1219-1228

田中良哉
全身性エリテマトーデス
成人病と生活習慣病(2012) 42, 954-957

田中良哉
膠原病と感染症
月刊糖尿病(2012) 4, 118-126

竹内勤、山中寿、田中良哉、田口敏彦
関節リウマチにともなう痛み
Practice of Pain Management(2012)3, 152-161

山岡邦宏、田中良哉
トファシチニブ(CP690550)
リウマチ科 (2012) 48, 299-303

田中良哉
目標達成に向けたリウマチ治療
日本内科学会雑誌(2012)101, 2865-2873

平田信太郎、田中良哉
X線による関節破壊評価
日本内科学会雑誌(2012)101, 2893-2898

田中良哉
細胞内シグナル制御による骨・免疫制御：治療への応用の可能性
Clinical Calcium(2012)22, 1747-1754

田中良哉
リウマチ専門医からみた関節痛を有する病変の病態と診断
日本医師会雑誌(2012)141, 1696-1700

田中良哉

インフリキシマブによるバイオフリー寛解の可能性

リウマチ科 (2012) 48, 620-626

平田信太郎、田中良哉

アダリムマブによるバイオフリー寛解の可能性

リウマチ科 (2012) 48, 636-640

齋藤和義、田中良哉

関節リウマチにおけるバイオフリー寛解の現状

臨床リウマチ(2012) 24, 307-313

田中良哉

関節リウマチとアディポサイトカイン

感染・炎症・免疫 (2012) 42, 349-353

Mori H, Okada Y, Yamaoka K, Saito K, Tanaka Y.

Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy.

J Bone Miner Metabolism (2012) 30, 114-118

Yoshimura R, Saito K, Terada T, Yunoue N, Umene-Nakano W, Hirata S, Saito K, Tanaka Y, Nakamura J.

Steroid psychosis in a polyarthritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally

Ann General Psychiatry (2012) 11, 2

Hirakawa E, Saito K, Hirata s, Atsumi T, Koike T, Tanaka Y.

A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/β 2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies

Mod Rheumatol (2012) 22, 769-773

Iwata S, Saito K, Hirata S, Tanaka Y.

Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy.

Ann Rheum Dis (2012) 71, 2058-2059

Yamamoto S, Okada Y, Mori H, Fukumoto S, Tanaka Y.

Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide: A case report.

Internal Med (2012) 51, 2375-2378

Torimoto K, Okada Y, Arao T, Mori H, Tanaka Y.

A case of zoledronate-induced tubulointerstitial nephritis with Fanconi Syndrome.

Endocrine J (2012) 59, 1051–1056

勝山隆行、齋藤和義、山岡邦宏、平田信太郎、辻村静代、名和田雅夫、田中良哉

両側網膜中心動脈閉塞症を契機に診断に至った Churg-Strauss 症候群の 1 例

九州リウマチ (2012) 32, 52–56

新生忠司、岡田洋右、成澤学、森博子、田中良哉

睡眠の改善により著明な QOL 向上と糖代謝改善を認めた重症閉塞型睡眠時無呼吸症の 2 例

Diabetes Frontier (2012) 23, 343–346

田中健一、岡田洋右、新生忠司、田中良哉

少量インスリンからリラグルチドへの変更が有用であった高齢者 2 型糖尿病の 2 例

Diabetes J (2012) 40, 81–85

元舞子、岡田洋右、新生忠司、森博子、田中良哉

集学的治療で救命した肝・心・腎不全合併甲状腺クリーゼの1例

内科 (2012) 110: 159–162

成澤学、岡田洋右、新生忠司、杉澤千穂、田中良哉

抗甲状腺薬長期内服中に生じた無顆粒球症の 2 例

内科 (2012) 110: 499–502

山本直、岡田洋右、西田啓子、松下幸司、新生忠司、田中良哉

アログリップチンとボグリボースの併用効果を持続血糖モニターで確認できた 1 例

糖尿病 (2012) 55, 705–709

水野泰志、齋藤和義、澤向範文、岩田慈、名和田雅夫、徳永美貴子、平田信太郎、山岡邦宏、田中良哉

肺多発空洞影を呈した結節性多発動脈炎(PN)の 1 例

九州リウマチ (2012) 32, 108–112

松下幸司、岡田洋右、西田啓子、新生忠司、田中良哉

高血糖を契機に後頭葉てんかんを発症し二次性全般化発作を伴った 2 型糖尿病の 1 例

Diabetes Frontier (2012) 23, 615–619

鳥本桂一、岡田洋右、森博子、新生忠司、田中良哉

リスプロ混合製剤-25 とアカルボーズの併用効果を持続血糖モニターで確認できた 1 例

Diabetes J (2012) 40, 129–132

黒住旭、岡田洋右、西田啓子、山本直、新生忠司、田中良哉

低血糖発作との鑑別が重要であった体位性起立頻脈症候群の1例

産業医科大学雑誌 (2012) 34, 353–361

平成25年(2013年)

Tanaka Y.

Next stage of RA treatment: TNF-inhibitor-free remission will be a possible treatment goal?

Ann Rheum Dis 72, ii124–ii127, 2013

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester G, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham III C, Bykerk V, Choy E, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop K, de Wit M, van der Heijde D.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Ann Rheum Dis 72, 482–492, 2013

Tanaka Y, Yamaoka K.

A Jak inhibitor tofacitinib for the treatment of rheumatoid arthritis from basic to clinic.

Mod Rheumatol 23, 415–424, 2013

O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A.

Janus kinase inhibitors in autoimmune diseases

Ann Rheum Dis 72, ii111–ii115, 2013

Tanaka Y, Hirata S, Saleem B, Emery P.

Discontinuation of biologics in patients with rheumatoid arthritis.

Clin Exp Rheumatol 31, S22–S27, 2013

Tanaka Y, Hirata S.

Is it possible to withdraw biologics from therapy in rheumatoid arthritis?

Clinical Therapeutics 35, 2028–2035, 2013

Oshita K., Yamaoka K., Kondo M., Tanaka Y.

Regulatory role of mesenchymal stem cells in osteoclast differentiation

Inflammation and Regeneration 33, 217–222, 2013

Mori H, Okada Y, Kishikawa H, Inokuchi N, Sugimoto H, Tanaka Y.

Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes.

J Bone Miner Metabolism 31, 89–95, 2013

Kameda H, Kanbe K, Sato e, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Yamanaka H, Takeuchi T.

A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study.

Ann Rheum Dis 72, 310–312, 2013

Aoki T, Yamashita Y, Saito K, Tanaka Y, Korogi Y.

Diagnosis of early-stage rheumatoid arthritis: usefulness of unenhanced and gadolinium-enhanced MR images at 3 T.

Clin Imaging 37, 348–353, 2013

van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA and the ORAL Scan investigators.

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12 month data from a 24 month Phase 3 randomized radiographic study.

Arthritis Rheum 65: 559–570, 2013

Tsuboi H, Hagiwara S, Asashima H, umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama S, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Matsumoto I, Sumida T.

Validation of diagnostic criteria for Sjogren's syndrome in Japanese patients.

Mod Rheumatol 23, 219–225, 2013

Toyota T, Akamatsu N, Tanaka A, Shouzaki T, Tsuji S, Saito K, Tanaka Y.

Mesial temporal lobe epilepsy as a neuropsychiatric syndrome of systemic lupus erythematosus.

Epilepsia 54, e33–e36, 2013

Iwata S, Saito K, Tokunaga M, Tanaka Y.

Persistent memory B cell down-regulation after 6-year remission induced by rituximab therapy in patients with systemic lupus erythematosus.

Lupus 22, 538–540, 2013

Arao T, Okada Y, Mori H, Nishida K, Tanaka Y.

Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.

Endocrine J 60, 563–570, 2013

Aoki T, Yamashita Y, Oki H, Takahashi H, Hayashida Y, Saito K, Tanaka Y, Korogi Y.

Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) of the wrist and finger at 3T: Comparison with chemical shift selective fat suppression images.

J Magn Reson Imaging 37, 733–738, 2013

Li X, Yamagata K, Nishita M, Endo M, Arfian N, Rikitake Y, Emoto N, Hirata K, Tanaka Y, Minami Y.

Activation of Wnt5a–Ror2 signaling associated with epithelial-to-mesenchymal transition (EMT) of tubular epithelial cells during renal fibrosis.

Genes Cells 18, 608–619, 2013

Kurozumi A, Okada Y, Mori H, Arao T, Tanaka Y.

Efficacy of α -glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (Alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring.

J Diabetes Invest 4, 393–398, 2013

Mori H, Okada Y, Tanaka Y.

Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia.

Diabetology International 4, 117–125, 2013

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D, and the GO-MONO study group.

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying anti-rheumatic drugs: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-MONO study through 24 weeks.

Ann Rheum Dis 72, 1488–1495, 2013

Mori T, Kabashima K, Fukamachi S, Kuroda E, Sakabe JI, Kobayashi M, Nakajima S, Nakano K, Tanaka Y, Matsushita S, Nakamura M, Tokura Y.

D1-like dopamine receptors antagonist inhibits cutaneous immune reactions mediated by Th2 and mast cells.

J Dermatol Sci 18, 608–619, 2013

Hanami K, Nakano K, Saito K, Okada Y, Yamaoka K, Kubo S, Kondo M, Tanaka Y.

Dopamine D2-like receptor signaling suppresses human osteoclastogenesis.

Bone 56, 1–8, 2013

Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Katsuki A, Saito K, Tanaka Y, Nakamura J.

Plasma catecholamine metabolite levels and the activities of psychiatric symptoms in systemic lupus erythematosus.

Hum Psychopharm Clin 28, 198–202, 2013

Hirata S, Driven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TWJ, Allaart CF.

A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.

Rheumatology 52, 1202–1207, 2013

Torimoto K, Okada Y, Mori H, Tanaka Y.

Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus.

Cardiovascular Diabetology 12:1, 2013

Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida s, Akama H, Kupper H, Aprora V, Tanaka Y.

Adalimumab a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Ann Rheum Dis 72, 1488–1495, 2013

Nakajima A, Saito K, Kojima T, Amano K, Yoshio T, Fukuda W, Inoue E, Momohara S, Minota S, Takeuchi T, Ishigura N, Tanaka Y, Yamanaka H.

No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan.

Mod Rheumatol 23, 945–952, 2013

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Hirose T, Yoshinaga T, Suzukawa M.

Safety and effectiveness of 6 months etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs

J Rheumatol 40, 1658–1668, 2013

Choo Q-Y, Ho P, Tanaka Y, Lin H-S.

Histone Deacetylase Inhibitors MS-275 and SAHA Suppressed p38 Mitogen Activated Protein Kinase Signaling Pathway and Chemotaxis in Rheumatoid Arthritic Synovial Fibroblastic E11 cells.

Molecules 18, 14085–14095, 2013

Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Discontinuation of adalimumab after attaining DAS28 (ESR) remission in patients with rheumatoid arthritis (HONOR study): an observational study.

Arthritis Res Ther 15 (5), 2013

Kondo M, Yamaoka K, Sonomoto K, Fukuyo S, Oshita K, Okada Y, Tanaka Y.

IL-17 inhibits chondrogenic differentiation of human mesenchymal stem cells.

Plos ONE 8 (11) , 2013

Torimoto K, Okada Y, Mori H, Hajime M, Tanaka K, Kurozumi A, Narisawa M, Yamamoto S, Arao T, Matsuoka H, Inokuchi N, Tanaka Y.

Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.

Lipids Health Disease 12(1) , 2013

Watanabe K, Sakai R, Koike R, Sakai f, Sugiyama H, Tanaka M, Komano y, Akiyama Y, Mimura T, Kaneko Y, Tokuda H, Iso T, Motegi M, Ikeda K, Nakajima H, Taki H, Kubota T, Kodama H, Sugii S, Kuroiwa T, Nawata Y, Shiozawa K, Ogata A, Sawada S, Matsukawa Y, Okazaki T, Murai M, Iwahashi M, Saito K, Tanaka Y, Nanki T, Miyasaka N, Harigai M.

Clinical characteristics and risk factors for *Pneumocystis jirovecii* pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.

Mod Rheumatol 23: 1085–1093, 2013

Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto K, Saito K, Tanaka Y.

Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis.

Mod Rheumatol 23: 1151–1157, 2013

Tanaka Y, Kawai S, Takeuchi T, Yamamoto K, Miyasaka N.

Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.

Mod Rheumatol 23: 1045–1052, 2013

田中良哉

関節リウマチ患者の実態調査～アンメットメディカルニーズの把握

新薬と臨床 62, 758–777, 2013

元舞子、岡田洋右、森博子、新生忠司、田中良哉

高齢2型糖尿病患者におけるメトホルミンの有用性

産業医科大学雑誌 34, 323–329, 2013

今村秀基、中塚敬輔、吾妻妙子、山崎政治、小辻英明、吉田泰憲、浦本秀隆、小山倫浩、田中良哉

Rheumatoid arthritis 患者に於ける糖尿病発症についての検討－3 施設共同研究－

臨床と研究 90, 811–813, 2013

今村秀基、中塚敬輔、吾妻妙子、山崎政治、小辻英明、吉田泰憲、浦本秀隆、小山倫浩、田中良哉

Polymyositis/dermatomyositis および systemic sclerosis 患者に於ける deabetes mellitus 発症についての
検討 -3 施設共同研究-
臨床と研究 90, 1101-1104, 2013

今村秀基、中塚敬輔、吾妻妙子、山崎政治、小辻英明、吉田泰憲、浦本秀隆、小山倫浩、田中良哉
Systemic lupus erythematosus 患者に於ける deabetes mellitus 発症についての検討 -3 施設共同研究-
臨床と研究 90, 1389-1392, 2013

田中良哉
グルココルチコイドと骨
Clinical Calcium (2013) 23, 229-235

山岡邦宏、田中良哉
細胞内分子標的薬と自己免疫
Pharma Medica (2013) 31, 51-55

前島圭佑、山岡邦宏、石井宏治、田中良哉
JAK 阻害薬トファシチニブの DMARDs 抵抗性 RA 患者への有効性
リウマチ科 (2013) 49, 68-73

田中良哉
リウマチ膠原病・アレルギー学
日本医事新報 (2013) 4632, 22-27

田中良哉
分子標的薬
腎と透析 (2013) 74, 81-87

山岡邦宏、齋藤和義、田中良哉
細胞内分子標的薬: JAK 阻害薬および Syk 阻害薬
臨床薬理 (2013) 44, 23-27

田中良哉
新規低分子化合物
CLINICIAN (2013) 616, 218-224

田中良哉
細胞表面抗原を標的とした生物学的製剤
medicina (2013) 50, 508-513

田中良哉
関節リウマチ治療に於ける骨・軟骨評価
Clinical Calcium (2013) 23, 409-417

田中良哉
免疫抑制薬
JOHNS (2013) 29, 611-615

田中良哉
ヒト間葉系幹細胞による破骨細胞の分化抑制作用と関節リウマチ治療への応用
産業医科大学雑誌 (2013) 35, 33-37

花見健太郎、中野和久、田中良哉
ドバミン受容体シグナルによる破骨細胞の分化制御
日本臨床免疫学会会誌 (2013) 36, 35-39

田中良哉
新たな作用機序を有する骨粗鬆症、リウマチ治療薬
実験医学 (2013) 31, 877-883

田中良哉
低分子化合物を用いた細胞内シグナル分子を標的とする治療
最新医学 (2013) 68, 692-703

田中良哉
腎と骨代謝の時代へ
腎と骨代謝 (2013) 26, 89-90

田中良哉
慢性炎症
内科 (2013) 111, 653-656

田中良哉
TNF 阻害薬
Medical Practice (2013) 30, 682-686

岡田洋右、田中良哉
血管石灰化と AGE/RAGE
医学のあゆみ (2013) 244, 675-679

平田信太郎、田中良哉

アダリムマブ

Rheumatology Clinical Research(2013) 2, 15-20

竹内勤、田中栄、桃原茂樹、田中良哉、渥美達也

関節リウマチ治療のこれからの課題と新しい生物学的製剤の役割

Rheumatology Clinical Research(2013) 2, 35-43

田中良哉、Michael Schiff、亀田秀人

関節リウマチの治療戦略を考える：治療早期の薬剤反応制による長期臨床予後の予測

Rheumatology Clinical Research(2013) 2, 44-52

中山田真吾、田中良哉

Th1 細胞と Tfh 細胞の多様性/可塑性とエピゲネティクス制御

臨床免疫(2013)59, 500-506

山岡邦宏、田中良哉

トファシチニブ

分子リウマチ治療(2013)6, 78-81

田中良哉、中山田真吾

CD28 活性化受容体標的療法(アバタセプト、ベラタセプト)

炎症と免疫(2013) 21, 182-188

岡田洋右、森博子、田中良哉

骨粗鬆症

日本内科学会雑誌(2013) 102, 907-913

田中良哉

関節リウマチの病因・病態と免疫異常

関節リウマチ(2013)71, 1147-1152

山岡邦宏、田中良哉

JAK 阻害薬

関節リウマチ(2013)71, 1243-1247

中野和久、田中良哉

関節リウマチのゲノムワイド DNA メチル化解析

リウマチ科(2013)49, 589-594

田中良哉

低分子量化合物による分子標的治療 ~トファシチニブを中心に~

実験治療(2013)710, 67-73

田中良哉

生物学的製剤による膠原病の治療

病理と臨床(2013)31, 770-777

山岡邦宏、田中良哉

JAK インヒビター

整形・災害外科(2013)56, 877-881

平田信太郎、田中良哉

セルトリズマブ:最近の新知見

リウマチ科(2013)50, 80-85

田中良哉

JAK 阻害薬はリウマチ治療にさらなる改革をもたらすことができるか

医薬ジャーナル(2013)49, 1973-1976

山岡邦宏、田中良哉

トファシチニブの作用機序

医薬ジャーナル(2013)49, 1993-1997

中山田真吾、田中良哉

新規 JAK/SYK 阻害薬の開発動向

医薬ジャーナル(2013)49, 2011-2015

辻村静代、齋藤和義、田中良哉

関節リウマチ

Medical Practice(2013)30, 1573-1575

田中良哉

免疫学からみた骨代謝

Clinical Calcium(2013)23, 1265-1270

山岡邦宏、田中良哉

新世代の経口抗リウマチ薬 -トファシチニブの有効性と安全性

薬事(2013)55, 1527-1530

田中良哉

発熱と倦怠感が主訴のリウマチ治療中の男性、鑑別診断は？

Rheumatology Clinical Research (2013) 2, 153–155

山岡邦宏、田中良哉

細胞内シグナル分子を標的にした RA 骨破壊制御

Rheumatology Clinical Research (2013) 2, 104–107

中野和久、田中良哉

RA 患者滑膜細胞における DNA メチル化

リウマチ科 (2013) 50, 370–375

山岡邦宏、田中良哉

新世代の経口抗リウマチ薬—トファニチニブの有効性と安全性

薬事 (2013) 55, 1527–1530

田中良哉

中枢神経ループスの診断と治療

BRAIN and NERVE (2013) 65, 1255–1267

齋藤和義、田中良哉

SLE の新たな治療標的

リウマチ科 (2013) 50, 583–590

平田信太郎、田中良哉

MBDA スコアによる RA 活動性評価

リウマチ科 (2013) 50, 618–622

齋藤和義、田中良哉

MTX+TNF 阻害薬による治療

Arthritis (2013) 11, 104–113

平田信太郎、田中良哉

臨床的寛解の判定基準を教えて下さい

Arthritis (2013) 11, 128–129

田中良哉

生物学的製剤ゴリムマブがもたらす新展開～寛解導入と維持の実践～

臨床リウマチ (2013) 25, 276–280

田中良哉

Jak 阻害薬の位置づけは？

Mebio (2013) 30, 82–89

Sugisawa C, Okada Y, Arao T, Mori H, Nishida K, Isobe K, Takekoshi K, Tanaka Y.

Juvenile-onset hereditary pheochromocytoma-paraganglioma syndrome

Internal Medicine (2013) 52, 281–284

Mori H, Okada Y, Arao T, Shimaziri S, Tanaka Y.

A case of multiple brown tumors with primary hyperparathyroidism.

J Bone Miner Metabolism (2013) 31, 123–127

Yamamoto S, Okada Y, Mori H, Kurozumi A, Torimoto K, Arao T, Tanaka Y.

Iatrogenic osteomalacia: report of two cases

J UOEH (2013) 35, 25–31

Yamamoto S, Okada Y, Mori H, Saito K, Inokuchi N, Tanaka Y.

Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. A case report

Mod Rheumatol (2013) 23, 401–405

Kurozumi A, Okada Y, Arao T, Nakamoto Y, Togashi K, Tanaka Y.

A case of multiple endocrine neoplasia 2B with probable ectopic adrenocorticotrophic hormone-secreting liver metastasis from medullary thyroid carcinoma

J UOEH (2013) 35, 193–199

Kurozumi A, Okada Y, Arao T, Endo I, Matsumoto T, Tanaka Y.

Extrapyramidal symptoms and advanced calcification of the basal ganglia in a patient with autosomal dominant hypocalcemia

Internal Medicine (2013) 52, 2077–2081

杉澤千穂、岡田洋右、新生忠司、西田啓子、田中良哉

糖尿病性神経因性膀胱が厳格な血糖コントロールで改善した 2 型糖尿病の 2 例

Diabetes Frontier (2013) 24, 95–99

黒住旭、岡田洋右、新生忠司、田中良哉

エキナセチド使用中に生じた胃不全麻痺による血糖変動に対するクエン酸モサブリドの有効性が CGM で確認できた 2 型糖尿病の 1 例

Diabetes J (2013) 41, 20–25

成澤学、岡田洋右、新生忠司、荻ノ沢泰司、田中良哉
洞不全症候群を伴う QT 延長症候群が甲状腺全摘出術後に顕性化した Basedow 病の1例
内科 (2013) 112: 192–197

成澤学、岡田洋右、新生忠司、森博子、田中良哉
2型糖尿病合併成人成長ホルモン分泌不全症に成長ホルモン補充療法が有効であった1例
内科 (2013) 112: 397–401

平成26年(2014年)

Yamaoka K, Tanaka Y.
Targeting the JAKs in rheumatoid arthritis: focus on tofacitinib.
Expert Opinion on Pharmacotherapy 15, 103–113, 2014

Kubo S, Yamaoka K, Tanaka Y.
Role of JAKs in myeloid cells and autoimmune diseases.
Inflammation and Regeneration 34, 129–133, 2014

Tanaka Y, Martin Mola E.
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.
Ann Rheum Dis 73, 1395–1397, 2014

Kondo M, Yamaoka K, Tanaka Y.
Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions.
International Journal of Molecular Sciences 15, 21270–21285, 2014

Tanaka Y, Hirata S.
Intensive intervention can lead to a treatment holiday from biological DMARD in patients with rheumatoid Arthritis.
Drugs 74, 2129–2139, 2014

Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Y, Tanaka Y.
Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: A retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.
Mod Rheumatol 24: 42–51, 2014

Fukuyo S, Saito K, Yamaoka K, Sawamukai N, Hirata S, Nawata M, Iwata S, Tanaka Y.
Efficacy and safety of reducing duration of infliximab infusion.

Mod Rheumatol 24, 273–280, 2014

Futatsuya K, Kakeda S, Kaichi Y, Moriya J, Ohnari N, Saito K, Tanaka Y, Korogi Y.

Systemic lupus erythematosus: prediction by MRI of the subsequent development of brain lesions.

Acad Radiol 21: 617–23, 2014

Katsuyama T, Saito K, Kubo S, Nawata M, Tanaka Y.

The prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.

Arthritis Res Ther 16: R43, 2014

Aoki T, Fujii M, Yamashita Y, Takahashi H, Oki H, Hayashida Y, Saito K, Tanaka Y, Korogi Y.

Tomosynthesis of the wrist and hand in patients with rheumatoid arthritis: comparison with radiography and MRI.

AJR Am J Roentgenol 202: 386–90, 2014

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y.

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events.

Rheumatology (Oxford) 53: 914–8, 2014

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H.

Characteristics related with good effectiveness and safety with tocilizumab: Postmarketing surveillance of 7901 rheumatoid arthritis patients in Japan

J Rheumatol 41:15–23, 2014

Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52 week results of the HOPEFUL-1 trial.

Rheumatology (Oxford). 53: 904–13, 2014

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Mod Rheumatol 24, 405–409, 2014

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa

T, Nagaswa H, Hoshi D, Sato E, Yamanaka H.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Mod Rheumatol 24, 399–404, 2014

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Haruna S, Uchida N, Kawana K, Tanaka Y.

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7,740 patients.

Mod Rheumatol 24, 390–398, 2014

Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M, Hitota T, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Mariyama M, Takeuchi T, Tanaka Y, Hirata S, Mimori T, Ohta A, Matsumoto I, Sumida T.

Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan.

Mod Rheumatol 24, 464–470, 2014

Mori H, Okada Y, Arao T, Tanaka Y.

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus.

J Diabetes Invest 5, 313–319, 2014

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watababe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.

Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial

Mod Rheumatol 24:552–60, 2014

Fukuyo S, Yamaoka K, Sonomoto K, Oshita K, Okada Y, Saito K, Yoshida Y, Kanazawa T, Minami Y, Tanaka Y.

IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3-dependent.

Rheumatology 53:1282–90, 2014

Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M; for the RESEARCH investigators; the REAL Study Group.

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.

Mod Rheumatol 24:572–9, 2014

Yamamoto S, Okada Y, Mori H, Nishida K, Uriu K, Tanaka Y.

The type 2 diabetes mellitus complicated by hypertension in Japanese patients: switching treatment from high-dose angiotensin II receptor blockers to losartan plus hydrochlorothiazide.

Intern Med 53:1283–9, 2014

Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y.

Guidelines on the Management and Treatment of Glucocorticoid-induced Osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update.

J Bone Miner Metabolism 32:337–5, 2014

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T.

Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M.

Fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab fracture intervention randomized placebo controlled trial (DIRECT).

J Clin Endocrinol Metabolism 99:2599–607, 2014

Torimoto K, Okada Y, Mori H, Tanaka Y.

Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes.

Cardiovascular Diabetology 13:99, 2014

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watababe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.

Mod Rheumatol 24, 715–724, 2014

Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watababe A, Origasa H, Shoji T, Miyasaka N, Koike T.

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of HIKARI study.

Mod Rheumatol 24, 725–733, 2014

Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.

Mod Rheumatol 24, 734–743, 2014

Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, Takeuchi T. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia® as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol 24, 754–762, 2014

Choo Q-Y, M-Y SC, Ho PC, Tanaka Y, Lin H-S. Pterostilbene surpassed resveratrol for anti-inflammatory application: potency consideration and pharmacokinetics perspective. Journal of Functional Foods 11, 352–362, 2014

Wang S-P, Iwata S, Nakayamada S, Sakata K, Yamaoka K, Tanaka Y. Tofacitinib, a Jak inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis 73, 2213–2215, 2014

Sakai R, Cho S-K, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Suhihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M, and for the REAL study group.

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients for long-term safety (REAL) database.

Rheumatol Int 34, 1729–1736, 2014

Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y. The JAK inhibitor tofacitinib reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 73, 2192–2198, 2014

Zhang X, Yamaoka K, Sonomoto K, Kaneko H, Satake M, Yamamoto Y, Kondo M, Zhao J, Miyagawa I, Yamagata K, Fukuyo S, Okada Y, Tanaka Y. Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats.

Plos ONE 9(12), 2014

Oshita K., Yamaoka K., Kondo M., Tanaka Y. Regulatory role of mesenchymal stem cells in osteoclast differentiation. Inflammation and Regeneration 33, 217–222, 2014

Kubo S, Yamaoka K, Maeshima K, Tanaka Y. The possible mode of action of Tofacitinib, a JAK inhibitor.

鈴木克典、真弓俊彦、矢寺和博、田中良哉、迎寛
肺炎球菌性肺炎患者に対するガレノキサシンの解熱効果の検討
新薬と臨床 63, 1172–1178, 2014

田中良哉
関節リウマチに於ける臓器障害
日本医師会雑誌(2014)142, 2241–2244

田中良哉
ペリムマブ:ループス腎炎
腎と透析(2014) 76, 96–100

斎藤和義、田中良哉
RAにおける抗 BAFF 抗体 tabalumab の有効性と安全性
リウマチ科(2014)51, 118–125

高崎芳成、竹内勤、田中良哉
リウマチ・膠原病の治療の現況と将来展望 -分子標的治療薬を中心に-
最新医学(2014)60, 191–203

中山田真吾、田中良哉
Syk/Btk 標的療法
最新医学(2014)60, 280–284

山岡邦宏、田中良哉
JAK 阻害薬
最新医学(2014)60, 285–289

山岡邦宏、田中良哉
トファシチニブの課題
臨床リウマチ(2014)26, 17–23

山岡邦宏、田中良哉
JAK 阻害薬と関節リウマチ
感染・炎症・免疫(2013)43, 247–249

田中良哉
骨と関節リウマチ

腎と骨代謝(2014)27, 121–128

田中良哉

リウマチ・膠原病に於ける分子標的治療の最前線 序論

最新医学(2014)69, 189–190

高崎芳成、竹内勤、田中良哉

リウマチ・膠原病の治療の現況と将来展望—分子標的治療薬を中心にして

最新医学(2014)69, 189–190

田中良哉

JAK 阻害薬

最新医学(2014)69, 285–290

田中良哉

2013 年欧州リウマチ学会議(EULAR)

Arthritis(2013) 11, 208–209

齋藤和義、田中良哉

インフリキシマブ

Mebio(2014) 31(5), 14–23

田中良哉

JAK 阻害薬： 使い方と安全性

Mebio(2014) 31(5), 74–81

中山田真吾、田中良哉

滤胞性ヘルパーT(Tfh)細胞と自己免疫疾患

九州リウマチ(2014)34, 12–16

田中良哉

炎症性疾患と骨代謝： 分子標的薬を中心に

実験医学(2014) 32, 1159–1165

山岡邦宏、田中良哉.

トファシチニブの安全性

リウマチ科(2014)51, 200–204

田中良哉、山岡邦宏

Jak/Stat now

分子リウマチ治療(2014)34, 12-16

中山田真吾、田中良哉。
濾胞性ヘルパーT(Tfh)細胞と自己免疫疾患
最新医学(2014)34, 12-16

田中良哉
関節 X 線による関節損傷評価
カレントテラピー(2014)32, 444-448

田中良哉
生物学的製剤
医学のあゆみ(2014)249, 401

田中良哉
生物学的製剤
Osteoporosis Japan (2014) 22, 342-346

岡田洋右、森博子、谷川隆久、橋本修、田中良哉
血管石灰化と骨
Osteoporosis Japan (2014) 22, 275-278

山形薰、山岡邦宏、田中良哉
Mesenchymal stem cell による関節リウマチ治療の可能性
臨床免疫・アレルギー科 (2014) 61, 560-564

田中良哉
生物学的製剤による関節疾患治療
Clinical Calcium (2014) 24, 911-917

園本格士朗、山岡邦宏、田中良哉。
間葉系幹細胞による関節リウマチの骨軟骨再生へのアプローチ
産業医科大学雑誌(2014)36, 141-146

染谷一貴、中野和久、田中良哉
関節リウマチと NETs
リウマチ科 (2014) 51, 454-459

岡田洋右、田中良哉
ステロイド性骨粗鬆症に対するビスホスホネートの効果

整形・災害外科 (2014) 57, 869–875

平田信太郎、田中良哉。
マルチバイオマーカーの臨床応用とその可能性
分子リウマチ治療 (2014) 34, 85–89

平田信太郎、田中良哉
BeSt 試験
リウマチ科 (2014) 52, 1–5

田中良哉
HOPEFUL 試験
リウマチ科 (2014) 52, 24–29

中山田真吾、田中良哉
早期予後不良 RA における MTX の有用性 (TEAR trial)
リウマチ科 (2014) 52, 83–88

山岡邦弘、田中良哉。
新しい分子標的療法—JAK 阻害薬—
Modern Physician (2014) 34, 935–938

田中良哉
ステロイド性骨粗鬆症の病因
Clinical Calcium (2014) 24, 1289–1294

久保智史、田中良哉
強皮症における nailfold videocapillaroscopu を用いた定量的評価と診断や病態把握における有用性と魅力
リウマチ科 (2014) 52, 321–325

田中良哉、山村隆、神田隆
分子標的薬治療の未来
BRAIN and NERVE (2014) 66, 1137–1147

岩田慈、中山田真吾、田中良哉
Btk 標的療法
分子リウマチ治療 (2014) 7, 198–201

岡田洋介、田中良哉
生活習慣病における骨粗鬆症治療とビスホスホネート

Clinical Calcium (2014) 24, 1689–1694

田中良哉

関節リウマチ ～これまでとこれから～

WHITE (2014) 2, 138–143

田中良哉

ステロイド性骨粗鬆症の診断と治療

Medical Practice (2014) 31, 1937–1942

山岡邦宏、田中良哉

樹状細胞の IL-10 産生とその制御

臨床免疫・アレルギー科 (2014) 62, 600–603

田中良哉

薬物療法: biological DMARD

Pharma Medica (2014) 22(12), 45–48

平田信太郎、田中良哉

MBDA スコア

Rheumatology Clinical Research (2014) 3, 160–164

平田信太郎、佐藤友梨恵、田中良哉

関節リウマチ治療中に出現した多発性肺結節をどのように鑑別するか？

Rheumatology Clinical Research (2014) 3, 207–211

Torimoto K, Okada Y, Arao T, Mori H, Yamamoto S, Narisawa M, Kurozumi A, Tanaka Y.

Glucose variability before and after treatment of a patient with Graves' disease complicated by diabetes mellitus: assessment by continuous glucose monitoring.

Endocrine J (2014) 61, 321–328

Hajime M, Okada Y, Mori H, Tanaka Y.

A case of teriparatide-induced severe hypophosphatemia and hypercalcemia.

J Bone Miner Metabolism (2014) 32, 601–604

Mori H, Okada Y, Arao T, Tanaka Y.

A case of parathyroid carcinoma with a highly aggressive clinical course

J UOEH (2014) 36, 243–249

田中健一、岡田洋右、森博子、田中良哉

骨粗鬆症との鑑別に骨型アルカリホスファターゼ、オステオカルシン測定が診断に有用であった骨軟化症の1例

内科 (2014) 113: 183–186

新生忠司、岡田洋右、松下幸司、森博子、田中良哉

強化インスリン療法、理学療法にて改善した糖尿病筋萎縮症の1例

内科 (2014) 113: 395–399

新生忠司、岡田洋右、松下幸司、山本直、田中良哉

Basedow 病術後の甲状腺ホルモン内服自己中断後に発症した pretibial myedema の1例

内科 (2014) 113: 788–792

松下幸司、岡田洋右、新生忠司、田中良哉

初診時 TSAb 陽性で euthyroid Graves' ophthalmopathy との鑑別に難渋した特発性外眼筋炎の1例

内科 (2014) 114: 352–356

元舞子、岡田洋右、森博子、田中良哉

慢性腎臓病合併 2 型糖尿病患者に対する新規 DPP-4 阻害薬テキサグリプチンの使用経験

新薬と臨床 (2014) 63, 1807–1812

成澤学、岡田洋右、新生忠司、久能美美、田中良哉

甲状腺腫瘍(Plummer 病)で心不全を繰り返した無表情型甲状腺機能亢進症の 1 例

産業医科大学雑誌 (2014) 36, 277–283

平成27年(2015年)

Nakayamada S, Tanaka Y.

Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.

Int J Rheum Dis 18, 208–18, 2015

Takeuchi T, Tanaka Y, Close D, Godwood A, Wu C-Y, Saurigny D.

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase 2a study.

Mod Rheumatol 25, 21–30, 2015

Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.

Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies.

Mod Rheumatol 25, 11–20, 2015

Kaneko Y, Koike T, Oda H, Yamamoto K, Mitasaka N, Harigai M, Yamanaka H, Ishiguro N, Tanaka Y, Takeuchi T.

Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice.

Mod Rheumatol 25, 43–9, 2015

Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Ann Rheum Dis 74, 389–395, 2015

Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang S-P, Yoshikawa M, Saito K, Tanaka Y.

Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: A potential target for abatacept therapy.

Arthritis Rheum 67, 63–73, 2015

Ishizaki J, Saito K, Nawata M, Mizuno Y, Tokunaga M, Sawamukai N, Tamura M, Hirata S, Yamaoka K, Hasegawa H, Tanaka Y.

Low complements and high titer of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus.

Rheumatology 54, 405–412, 2015

Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Makano t, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T.

Three-Year Denosumab Treatment in Postmenopausal Japanese Women and Men with Osteoporosis: Results from a 1-year Open-label Extension of the Denosumab fracture Intervention RandomizEd placebo Controlled Trial (DIRECT).

Osteoporosis Int 26, 765–774, 2015

Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi T, Ebe H, Yokosawa M, Hagiya C, Asashima H, Takai C, Miki H, Umeda N, Kondo Y, Ogishima H, Suzuki T, Hirata S, Saito K, Tanaka Y, Horai Y, Nakamura H, Kawakami A, Sumida T.

Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's syndrome Endocrinopathy) trial; An open label, 1 year, prospective, and observational study Interim analysis of 32 patients for 24 weeks.

Mod Rheumatol 26, 187–193, 2015

Sakai S, Cho SK, Nanki T, Watanabe K, Uamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hyashi T, Sugihara T, Dobashi H, Atsumi T, Sawada T, Ezawa K, Ishigatubo Y, Mimori T, Migita T, Miyasaka N, Harigai M, for the REAL Study Group.

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.

Arthritis Res Ther 17(1): 74, 2015

Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shone E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomira A and the MUSASHI study investigators.

Safety and efficacy of various dosages of ocrelizumab in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate therapy: a placebo-controlled, double-blind, parallel-group study.

J Rheumatol 42: 799–809, 2015

Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka Y, Nanki T, Watanabe K, Yasuda S, Kurita T, Kaneko Y, Tanaka Y, Nishioka Y, Takasaki Y, Nagasaka K, Nagasawa H, Tohma S, Dohi M, Sugihara T, Sugiyama H, Kawaguchi Y, Inase N, Ochi S, Hagiwara H, Kohsaka H, Miyasaka N, Harigai M.

Assessment of risks for pulmonary infection during 12 months after commencing or intensifying immunosuppressive treatment for active connective tissue diseases: A report from a large-scale prospective cohort study.

J Rheumatol 42: 614–22, 2015

Kondo M, Yamaoka K, Sakata K, Sonomoto K, Lin L, Nakano K, Tanaka Y.

IL-6/STAT3 signaling pathway contributes to chondrogenic differentiation of human mesenchymal stem cells.

Arthritis Rheum 67, 1250–60, 2015

Hirata S, Li W, Defranoux N, Cavet G, Bolce R, Yamaoka K, Saito K, Tanaka Y.

A Multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with three tumor necrosis factor inhibitors.

Mod Rheumatol 25, 344–9, 2015

Takeuchi T, Matsubara T, Ohata S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N.

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicenter, observational study in Japan.

Rheumatology 54, 683–91, 2015

Torimoto K, Okada Y, Mori H, Otsuka T, Kawaguchi M, Matsuda M, Kuno F, Sugai K, Sonoda S, Hajime M, Tanaka K, Arao T, Tanaka Y.

Effects of exenatide on postprandial vascular endothelial function in type 2 diabetes mellitus.

Iwata S, Yamaoka K, Niilo H, Jabbarzadeh-Tabrizi S, Wang S-P, Kondo M, Yoshikawa M, Akashi K, Tanaka, Y.

Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.

Lupus 24: 695–704, 2015

Arao T, Okada Y, Torimoto K, Kurozumi A, Narisawa M, Yamamoto S, Tanaka Y.

Prednisolone dosing regimen for treatment of subacute thyroiditis.

J UOEH 37: 103–110, 2015

Yamanaka H, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Tanaka Y, Suzuki H, Shinmura Y, Koike T.

Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.

Mod Rheumatol 25, 495–502, 2015

Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S.

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

Mod Rheumatol 24, 514–521, 2015

Mori H, Okada Y, Tanaka Y.

Incidence of vitamin D deficiency and its relevance to bone metabolism in Japanese postmenopausal women with type 2 diabetes mellitus.

Internal Med 54, 1599–1604, 2015

Lin L, Yamagata K, Nakayamada S, Sawamukai N, Yamaoka K, Sakata K, Nakano K, Tanaka Y.

Histamine inhibits differentiation of skin fibroblasts into myofibroblasts.

Biochem Biophys Res Commun 463, 434–439, 2015

Wang SP, Iwata S, Nakayamada S, Niilo H, Jabbarzadeh-Tabrizi S, Kondo M, Kubo S, Yoshikawa M, Tanaka Y. Amplification of IL-21 signaling pathway through Bruton's tyrosine kinase in human B cell activation.

Rheumatology 54, 1488–1497, 2015

Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y.

14-3-3eta seropositive status is associated with more severe RA, its serial decrease informs better clinical outcomes and baseline levels predict DAS28 remission with Tocilizumab.

Arthritis Res Ther 17: 280, 2015

Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Otsubo H, Lee SJ, Nambu Y.
Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
Mod Rheumatol 25: 817–824, 2015

Hirata S, Tanaka Y.
Combination therapy for early rheumatoid arthritis; from perspective of treatment holiday.
Expert Review of Clinical Pharmacology 8, 115–122, 2015

Kondo M, Yamaoka K, Tanaka Y.
Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions.
Int J Mol Sci 17, 21270–85, 2015

Tanaka Y.
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
J Biochem 158, 173–179, 2015

Tanaka Y.
Human mesenchymal stem cells as a tool for joint repair in RA.
Clin Exp Rheumatol 33, S58–S62, 2015

Tsujimura S, Tanaka Y.
Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis.
World Journal of Experimental Medicine 5, 225–231, 2015

Hirata S, Defranoux N, Hanami K, Yamaoka K, Tanaka Y.
A multi-biomarker disease activity score for monitoring rheumatoid arthritis.
Current Biomarker Findings 5, 69–78, 2015

Terao C, Matsumura T, Yoshifiji H, Kirino Y, Maejima Y, Nakaoka Y, Takahashi M, Amiya E, Tamura N, Nakajima T, Origuchi T, Horita T, Matsukura M, Kochi Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Wada Y, Narita I, Kawaguchi Y, Yamanaka H, Ohmura K, Atsumi T, Tanemoto K, Miyata T, Kuwana M, Komuro I, Tabara Y, Ueda A, Isobe M, Mimori T, Matsuda F.
Takayasu arteritis and ulcerative colitis -high concurrence ratio and genetic overlap.
Arthritis Rheumatol 67, 2226–2232, 2015

田中良哉
分子標的治療
医学のあゆみ (2015) 252, 117–122

中山田真吾、田中良哉
ヒトヘルパーT 細胞サブセットの多様性と病態に於ける役割
医学のあゆみ (2015) 252, 55-60

田中良哉
リウマチ治療のドラックホリデーの可能性:HONOR 試験の結果を中心に
リウマチ科 (2015) 53, 63-68

園本格士朗、山岡邦宏、田中良哉
トファシチニブのリンパ球への影響と臨床効果および副作用との関連性
リウマチ科 (2015) 53, 77-81

中山田真吾、田中良哉.
抗 CD20 抗体と抗 CD22 抗体の国内外の動向
分子リウマチ治療(2015)8, 4-8

中山田真吾
膠原病の難病患者への就労支援
労働の科学(2015) 70, 550-553

平田信太郎、田中良哉
高齢者での生物学的製剤使用時の注意点
内科(2015) 115, 433-437

田中良哉、吉川浩男、佐藤伸一、小倉高志、武井卓
ステロイド性骨粗鬆症にどのように関与すべきか
Mainichi Medical Journal(2015) 11, 46-50

田中良哉
抗リウマチ薬の上手な飲み方
難病と在宅ケア (2015) 20 (3) 44-47

好川真以子、中山田真吾、岩田慈、久保智史、湯之上直樹、汪曉楓、田中良哉
全身性エリテマトーデス(SLE)患者 B 細胞に於けるケモカイン受容体発現異常
日本臨床免疫学会会誌 (2015) 38, 65-68

田中良哉
全身性エリテマトーデス
薬局 (2015) 66, 1722-1727

田中良哉

JAK 阻害薬

Rheumatology Clinical Research (2015) 4, 13–18

久保智史、齋藤和義、田中良哉

tofacitinib の first-line drug としての可能性

リウマチ科 (2015) 53, 369–373

田中良哉、園本格士朗、近藤真弘、尾下浩一、張香梅、福與俊介、山岡邦宏

間葉系幹細胞を用いた炎症性関節炎の治療と再生

日本臨床免疫学会会誌 (2015) 38, 86–92

黒住旭、岡田洋右、中野和久、田中良哉

血管石灰化とビスホスホネート

Clinical Calcium (2015) 25, 723–728

田中良哉、林直人、クリストファー・テリリアン

SLE に対するアタシセプトによる治療の可能性—APRIL 試験の結果などから

リウマチ科 (2015) 53, 522–530

田中良哉

低分子標的薬

カレントテラピー (2015) 33, 813–818

中山田真吾、田中良哉

バイオナイーブあるいは TNF 阻害薬抵抗性 RA 患者に対する抗 IL-17 抗体 ixekizumab の効果

リウマチ科 (2015) 54, 99–103

宮川一平、中山田真吾、田中良哉

ベーチェット病

炎症と免疫 (2015) 54, 432–436

田中良哉

関節リウマチに対する baricitinib

Rheumatology Clinical Research (2015) 4, 130–135

田中良哉

新規生物学的製剤(TNF/IL-6 阻害薬以外)

BIO Clinica (2015) 30, 1053–1057

田中良哉

間葉系幹細胞を用いた軟骨再生と炎症制御の可能性

Keynote RA (2015) 3, 185–189

田中良哉

副腎皮質ステロイド(骨粗鬆症・骨壞死)

リウマチ科 (2015) 54, 365–368

岩田慈、田中良哉

自己免疫疾患に於けるT細胞–B細胞相互作用の重要性

日本臨床免疫学会雑誌 (2015) 38, 398–402

久保智史、田中良哉

実地臨床において膠原病を疑う手指診察のポイント

日本臨床免疫学会雑誌 (2015) 38, 1131–1136

田中良哉

関節リウマチのパラダイムシフトと新展開

CLINICAL CALCIUM (2015) 25, 1747–1748

平田信太郎、田中良哉

関節リウマチの骨・軟骨病変の画像評価

CLINICAL CALCIUM (2015) 25, 1777–1785

中山田真吾、田中良哉

関節リウマチの骨・軟骨病変への抗RANKL抗体の応用

CLINICAL CALCIUM (2015) 25, 1787–1793

平田信太郎、田中良哉

生物学的製剤開始時期と種類をどう決定するか

リウマチ科 (2015) 54, 497–502

園本格士朗、田中良哉

トファシチニブのリンパ球への影響と臨床効果及び副作用との関連性

日本臨床免疫学会雑誌 (2015) 38, 443–447

Kurozumi A, Okada Y, Arao T, Narisawa M, Torimoto K, Yamamoto S, Tanaka Y.

Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: A case report.

Narisawa M, Okada Y, Arao T, Kuno F, Tanaka Y.

Hyperthyroidism with Heart Failure in an Elderly Patient with Plummer's Disease.

J UOEH (2014) 36, 277–83

Yamamoto S, Okada Y, Arao T, Tanaka Y.

Secondary adrenocortical insufficiency complicated by marked hypercalcemia and eosinophilia: a case report.

J UOEH (2015) 37, 55–60

Kuno F, Okada Y, Arao T, Kurozumi A, Tanaka Y.

Case of Graves' disease with remarkable psychiatric symptoms.

J UOEH (2015) 37, 49–53

森博子、岡田洋右、田中良哉

突然の多発骨折を認めた原因不明男性骨粗鬆症の1例

内科 (2015) 115: 333–337

山本直、岡田洋右、新生忠司、田中良哉

著明な高カルシウム血症と末梢血好酸球增多を呈した続発性副腎皮質機能低下症の1例

産業医科大学雑誌 (2015) 37, 55–60

久能英美、岡田洋右、新生忠司、黒住旭、田中良哉

著明な精神症状を呈したバセドウ病の1例

産業医科大学雑誌 (2015) 37, 49–53

松下幸司、岡田洋右、新生忠司、近藤秀臣、田中良哉

化膿性仙腸関節炎、恥骨骨破壊を伴い傍脊柱筋と骨盤周囲筋に巨大膿瘍形成した2型糖尿病の1例

糖尿病 (2015) 58: 115–120

齋藤昌大、花見健太郎、澤向範文、中野和久、齋藤和義、田中良哉

α -グルコシダーゼ阻害薬による腸管気腫症を認めた Clinically amyopathic dermatitis (CADM) の1例

九州リウマチ (2015) 35: 54–60

森博子、岡田洋右、川口真悠子、日浦政明、阿部慎太郎、柴瑛介、島尻正平、原田大、田中良哉

イプラグリフロジンを含めた総合的治療が血糖、NASHによる肝機能障害の改善につながった2型糖尿病の1例

糖尿病 (2015) 58: 286–292

松下幸司、岡田洋右、新生忠司、田中良哉

血管石灰化を伴う内頸動脈狭窄症をきたした家族性低カルシウム尿性高カルシウム血症の1例
内科 (2015) 116: 707-711

新生忠司、岡田洋右、鳥本桂一、山本直、田中良哉
組織診断に難渋し経過中腫脹内出血により気道狭窄をきたした甲状腺分化がんの1例
内科 (2015) 116: 889-894

元舞子、岡田洋右、森博子、田中良哉
週1回 GLP-1受容体作動薬エキセナチド LAR の効果を CGM で確認できた2型糖尿病の1例
Diabetes J (2015) 43, 153-157

平成28年(2016年)

Tanaka Y.
Current concepts in the management of rheumatoid arthritis.
Korean J Intern Med pp.210-218, 2016

Tanaka Y, Senoo A, Fujii H, Baker D.
Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.
Expert Opin Drug Metab Toxicol pp.319-326, 2016

Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR.
The changing landscape of biosimilars in rheumatology.
Ann Rheum Dis pp.974-982, 2016

Iwata S, Tanaka Y.
B cell subsets, signaling and their roles in secretion of autoantibodies.
Lupus pp.850-6, 2016

Kubo S, Nakayamada S, Tanaka Y.
Baricitinib for the treatment of rheumatoid arthritis.
Expert Rev Clin Immunol 12, 911-919, 2016

Tanaka Y.
Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine.
Clin Exp Rheumatol pp.49-52, 2016

Iwata S, Tanaka Y.
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of

rheumatoid Arthritis.

Expert Review of Clinical Immunology pp.11047–1057

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis.

BioDrugs 30, 407–419, 2016

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

Chemical JAK inhibitors for the treatment of rheumatoid arthritis

Expert Opin Pharmacother 17, 2215–2225, 2016

Tanaka Y.

Stopping TNF-targeted biological DMARDs in rheumatoid arthritis.

Rheumatology pp.ii15–ii22, 2016

Kubo S, Tanaka Y.

Usefulness of nailfold videocapillaroscopy for systemic sclerosis.

Inflammation and Regeneration pp.5, 2016

Nakayamada S, Tanaka Y.

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

Inflammation and Regeneration 36, 6, 2016

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.

The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Ann Rheum Dis 75: 75–83, 2016

Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, Endo K, Mashino N, Yamamoto K.

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus including lupus nephritis who are refractory to conventional therapy.

Mod Rheumatol 26, 80–86, 2016

Tsuru T, Tanaka Y, Kishimoto M, Saito K, Yoshizawa S, Takasaki Y, Miyamura T, Niijo H, Morimoto S, Yamamoto J, Lledo-Garcia R, Shao J, Tatematsu S, Togo O, Koike T.

Safety, Pharmacokinetics and Pharmacodynamics of Epratuzumab in Japanese Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from a Phase 1/2 Randomized Study.

Mod Rheumatol 66, 87–93, 2016

Takeuchi T, Tanaka y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, We JC, Shao J, Togo O, Mashmo H.

Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial.

Mod Rheumatol 66, 15–23, 2016

Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase 3, multicenter, randomized, double-blind, placebo-controlled study.

Ann Rheum Dis 75, 323–331, 2016

Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Hiramatsu K. Takeuchi T.

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1-year outcomes of the HOPEFUL-2 study.

RMD Open 2, 2016

Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.

Arthritis Res Ther 18(1):34, 2016

Tanaka Y, Zwillich SH.

Response to Dr. Minota's letter to the editor of Modern Rheumatology.

Mod Rheumatol 26, 318–319, 2016

Sonomoto K, Yamaoka K, Kaneko H, Yamagata K, Sakata K, Zhang X, Kondo M, Zenke Y, Sabanai K, Nakayamada S, Sakai A, Tanaka Y.

Spontaneous differentiation of human mesenchymal stem cells on poly-lactic-co-glycolic acid nano-fiber scaffold.

Plos ONE 11(4) , 2016

Nawata A, Noguchi H, Mazaki Y, Kurahashi T, Izumi H, Wang K. Guo X, Uramoto H, Kohno K, Taniguchi H, Tanaka Y, Fujii J, Sasaguri Y, Tanimoto A, Nakayama T, Yamada S.

Overexpression of peroxiredoxin 4 affects intestinal function in a dietary mouse model of nonalcoholic fatty liver disease.

Plos ONE 11(4) , 2016

Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W.

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis on background methotrexate therapy: A 12-week, double-blind, randomized placebocontrolled study.

J Rheumatol 43: 504–511, 2016

Ogasawara A, Kakeda S, Watanabe K, Ide S, Ueda I, Murakami Y, Moriya J, Futatsuya K, Sato T, Nakayamada S, Saito K, Tanaka Y, Liu T, Wang Y, Korogi Y.

Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia.

Eur Radiol 26: 1056–1063, 2016

Kinoshita S, Aoki T, Takahashi H, Oki H, Hayashida Y, Saito K, Tanaka Y, Korogi Y.

Thin-section chest CT findings in polymyalgia rheumatica: a comparison between with and without rheumatoid arthritis.

Clin Imaging 40, 382–385, 2016

Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, Kaneko Y.

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in moderate to severe rheumatoid arthritis patients in Japan: A 12-week, randomized, double-blind, placebo-controlled phase IIb study

Ann Rheum Dis 75, 1057–1064, 2016

Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda Y, Ohira T, Okuno N, Gennant HK, van der Heijde D.

Effect of Denosumab on Japanese Patients with Rheumatoid Arthritis: A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate to Validate Inhibitory Effect on Bone Erosion (DRIVE) -A Twelve-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial-

Ann Rheum Dis 75, 983–990, 2016

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Ishii Y, Nakajima H, Baker D, Miyasaka N, Koike T.

Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH Study.

Mod Rheumatol 26, 323–330, 2016

Winthrop K, Park SH, Gui A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H.

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.

Ann Rheum Dis 75, 1133–1138, 2016

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Baker D, Ishii Y, Yoshinari T, and the GO-FORTH study group.

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: Final results of the randomized GO-FORTH trial.

Mod Rheumatol 26, 481–490, 2016

Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, Hanami K, Saito K, Tanaka Y.

Comparison of efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by a propensity score-matching.

Ann Rheum Dis 75, 1321–7, 2016

Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Kobayashi M, Shoji T, Togo O, Miyasaka N, Koike A.

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.

Mod Rheumatol 26, 473–480, 2016

Haraigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Watanabe M, Tamada H, Koike T.

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis.

Mod Rheumatol 26, 491–8, 2016

Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, Fautrel B, van Vollenhoven R.

Tapering biologic and conventional DMARD therapy in rheumatoid arthritis – Current evidence and future directions.

Ann Rheum Dis 75, 1428–1437, 2016

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Takasaki Y, Mimori T, Hiramatsu K, Komatsu S, Tanaka Y.

Effect of methotrexate plus adalimumab on the achievement of rheumatoid arthritis therapeutic goals: Post-hoc analysis of Japanese patients (MELODY study).

Rheumatol Ther 3, 129–141, 2016

Kurozumi A, Okada Y, Mori H, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.

Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.

Endocrine J 63, 431–440, 2016

Kawahara T, Suzuki G, Inazu T, Mizuno S, Kasagi F, Okada Y, Tanaka Y.

Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomized, double-blind, placebo-controlled study.

BMJ Open 6, 2016

Thurmond RL, Greenspan A, Radziszewski W, Xu XL, Miao Y, Chen B, Ge T, Zhou B, Baker DG, Pavlova D, Ritchlin C, Tanaka Y, Takeuchi T, Smolen JS.

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.

J Rheumatol 43: 1637–1642, 2016

Yamanaka H, Nagaoka S, Kasama T, Haraoka H, Nishioka Y, Ueki Y, Seto Y, Nishinarita M, Tamura N, Kimura N, Saito K, Tomita T, Nawata Y, Suzuki S, Ishigatubo Y, Munakata Y, Makino Y, Inoue E, Tanaka Y, Takeuchi T.

Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity. –Results from the ENCOURAGE study, a prospective, international, multicenter randomized study– Modern Rheumatology.

Mod Rheumatol 26: 651–661, 2016

Zhao J, Kubo S, Nakayamada S, Shimajiri S, Zhang X, Yamaoka K, Tanaka Y.

Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome.

Mod Rheumatol 26: 716–724, 2016

Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, Saito K, Tanaka Y.

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.

Clin Exp Rheumatol 34, 834–841, 2016

Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T.

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Ann Rheum Dis 75, 1917–1923, 2016

Kurozumi A, Okada Y, Arao T, Tanaka Y.

Excess visceral adipose tissue worsens vascular endothelial function in patients with type 2 diabetes mellitus. Internal Medicine 55, 3091–3095, 2016

Tanaka Y, Mori H, Aoki T, Atsumi T, Kawahito Y, Nakayama H, Tohma S, Yamanishi Y, Hasegawa H, Tanimura K, Negoro N, Ueki Y, Kawakami A, Eguchi K, Saito K, Okada Y.

Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high dose glucocorticoid. Early Diagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) Study.

J Bone Miner Metabolism 34, 646–654, 2016

Hirata S, Li W, Kubo s, Fukuyo S, Mizuno Y, Hanami K, Sawamukai N, Yamaoka K, Saito K, Defranoux N, Tanaka Y.

Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.

Mod Rheumatol 26, 850–856, 2016

Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi T, Ebe H, Yokosawa M, Yagishita M, Takahashi H, Kurata I, Ohyama A, Honda F, Asashima H, Miki H, Umeda N, Kondo Y, Hirata S, Saito K, Tanaka Y, Horai Y, Nakamura H, Kawakami A, Sumida T.

Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial.

Mod Rheumatol 26, 891–899, 2016

Nawata M, Saito K, Fukuyo S, Hirata S, Tanaka Y.

Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1 year treatment with infliximab.

Mod Rheumatol 26, 807–812, 2016

Fuji M, Aoki T, Okada Y, Mori H, Kinoshita S, Hayashida Y, Hjime M, Tanaka K, Tanaka Y, Korogi Y.

Femoral neck strength prediction of diabetes mellitus patients by trabecular bone analysis using tomosynthesis images.

Radiology 28, 933–939, 2016

Fleischmann R, Kremer J, Tanaka Y, Grube D, Kanik K, Koncz T, Krishnaswami S, Wallenstein G, Wilkinson B, Zwillich S, Keystone E.

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key phase 2 studies.

Int J Rheum Dis 19, 1216–1225, 2016

Terao C, Ikari K, Nakayamada S, Takahashi Y, Yamada R, Ohmura K, Hashimoto M, Furu M, Ito H, Fujii T, Yoshida S, Saito K, Taniguchi A, Momohara S, Yamanaka H, Mimori T, Matsuda F.

A twin study of rheumatoid arthritis in the Japanese population

Kurozumi A, Okada Y, Arao T, Miyazaki Y, Yoshikawa M, Torimoto K, Kubo S, Nakayamada S, Tanaka Y.
Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report.

Endocrinol Diabetes Metab Case Rep 2016; 160020, 2016

新生忠司、岡田洋右、成澤学、西田啓子、田中良哉
精神疾患を合併した病的肥満症に対する認知行動療法の有用性とその適応
Diabetes Frontier 27, 93–98, 2016

田中良哉
トファシチニブのリンパ球への影響と臨床効果及び副作用との関連性
Bone Joint Nerve (2016) 6, 163–168

近藤真弘、山岡邦宏、田中良哉
ヒト間葉系幹細胞の軟骨分化におけるシグナル伝達機構
リウマチ科 (2016) 55, 82–87

中山田真吾、田中良哉
自己免疫疾患における濾胞性ヘルパーT(Tfh)細胞
日本臨床免疫学会雑誌 (2016) 39, 1–7

平田信太郎、田中良哉
Multi-biomarker disease activity (MBDA) score による関節リウマチの活動性評価
日本臨床免疫学会雑誌 (2016) 39, 37–41

田中良哉
RA 治療「寛解」の次なる目標 ～バイオフリーの可能性について～
CLINICIAN (2016) 646, 177–182

田中良哉
ステロイド性骨粗鬆症
The BONE (2016) 30, 71–75

中山田真吾、久保智史、田中良哉
アバタセプトの作用機序の新知見
九州リウマチ (2016) 36, 8–13

平田信太郎、田中良哉

バイオシミラー・バイオフリーについて:治療費軽減対策

内科 (2016) 117, 1195-1201

中山田真吾、田中良哉

B 細胞標的治療

Rheumatology Clinical Research (2015) 5, 24-30

平田信太郎、田中宏明、中野和久、田中良哉

鑑別すべき肺疾患について

Rheumatology Clinical Research (2015) 5, 63-68

平田信太郎、田中良哉

関節リウマチの新しい評価法 -MBDA スコアによる RA の活動性評価

日本臨床 (2016) 74, 931-937

田中良哉

トファシチニブ

日本臨床 (2016) 74, 974-980

平田信太郎、田中良哉

バイオフリー寛解・ドラッグフリー寛解の現状

リウマチ科 (2016) 55, 488-495

岩田慈、田中良哉

ヒト B 細胞シグナルにおける Syk の役割

炎症と免疫 (2016) 24, 340-346

久保智史、田中良哉

プロペンシティスコア

炎症と免疫 (2016) 24, 355-357

岡田洋右、田中良哉

1 型プロコラーゲン・N-プロペプチド(P1NP)

リウマチ科 (2016) 55, 596-599

田中良哉

バイオフリー寛解の導入と維持

リウマチ科 (2016) 56, 32-37

田中良哉

間葉系幹細胞の応用により関節リウマチ患者の関節の再生は可能か？

分子リウマチ治療 (2016) 9, 116–121

田中良哉

膠原病に於ける再生医学へのアプローチ

BIO Clinica (2016) 5, 105–110

田中良哉

SLE 脳症

BRAIN and NERVE (2013) 68, 1035–1048

中山田真吾、久保智史、田中良哉

自己免疫疾患におけるリンパ球サブセット解析の新展開

リウマチ科 (2016) 56, 317–323

中山田真吾、田中良哉

濾胞性ヘルペスT 細胞

炎症と免疫 (2016) 24, 470–476

中山田真吾、田中良哉

Tfh 細胞の病的意義

最新医学 (2016) 71, 2314–2319

田中良哉

関節リウマチに対する baricitinib の有効性と安全性

リウマチ科 (2016) 56, 499–507

中野和久、田中良哉

生物学的製剤の使い方と今後の動向

診断と治療 (2016) 104, 1557–1562

Torimoto K, Okada Y, Mori H, Tanaka Y.

Two sisters with Graves' disease and similar clinical features who tested positive for anti-insulin antibodies after thiamazole treatment

Internal Medicine (2016) 55, 1125–1129

Kurozumi A, Okada Y, Mor H, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.

Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes.

Endocrine J (2016) 63, 631–640

Mori H, Okada Y, Kawaguchi M, Tanaka Y.

A case of type 2 diabetes with a change from a non-dipper to a dipper blood pressure pattern by dapagliflozin.
J UOEH (2016) 38, 149–153

Kurozumi A, Okada Y, Arao T, Tanaka Y.

A case of resistance of thyroid hormone (RTH) with a negative family history with diagnosis based on persistent palpitations.

J UOEH (2016) 38, 291–296

大塚隆史、岡田洋右、新生忠司、元舞子、田中良哉

治療自己中断による血糖コントロール増悪にて発症した糖尿病性舞蹈病の1例

内科 (2016) 117: 155–158

久能英美、岡田洋右、鳥本桂一、田中良哉

ビルダグリプチンとミチグリニド/ボグリボース配合錠の併用による食後の血糖改善効果を CGM により確認した1例

Calm (2016) 3: 18–19

松下幸司、岡田洋右、森博子、田中良哉

妊娠中期に発症し出産後も遷延した中枢性尿崩症の1例

内科 (2016) 118: 145–148

新生忠司、岡田洋右、鳥本桂一、西田啓子、田中良哉

糖尿病患者の総胆管結石に伴う胆管炎に MRCP が早期診断に有用であった1例

Diabetes Journal (2016) 44, 150–154

平成29年(2017年)

Tanaka Y.

DMARD de-escalation — let the patient guide you.

Nature Reviews Rheumatology (2017) 13, 637–638

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Camen Morales L, Gonzaga JR, Yakushin s, Ishii T, Emoto K, Veatlie S, Arora V, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y.
Baricitinib versus placebo or adalimumab in rheumatoid arthritis.

New Engl J Med 376, 652–662, 2017

Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, Lee SJ, Nambu Y.

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab.

Mod Rheumatol 27, 237–245, 2017

Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kovacs B, Kariyasu S.

Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: subgroup analyses of the ILLUMINATE-1 study.

Mod Rheumatol 27, 284–291, 2017

Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, and Yamanaka H.

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio Study.

Mod Rheumatol 27, 217–226, 2017

Mori H, Okada Y, Kurozumi A, Narisawa M, Tanaka Y.

Factors influencing inter-day glycemic variability in diabetic outpatients on insulin therapy.

J Diabetes Invest 8, 69–74, 2017

Tanaka K, Okada Y, Mori H, Miyazaki M, Kuno F, Sonoda S, Sugai K, Hajime M, Kurozumi A, Narisawa M, Torimoto K, Arao T, Mine S, Tanaka Y.

Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.

Endocrine J 64, 179–189, 2017

Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, Agata N, Takeuchi T.

Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.

Arthritis Res Ther 19:56, 2017

Arao T, Okada Y, Torimoto K, Sugai K, Otsuka T, Kurozumi A, Tanaka Y.

Comparison between effectiveness of 100 mg/day sitagliptin and a switch to mitiglinide calcium hydrate/voglibose from 50 mg/day sitagliptin in patients with type 2 diabetes.

J UOEH 39, 1–9, 2017

Aletaha D, Bingham III CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.

Efficacy and safety of sirukumab, an anti-IL-6 cytokine monoclonal antibody, in patients with active rheumatoid arthritis despite anti-TNF therapy: results from the randomized, double-blind, placebo-controlled, global, phase 3 SIRROUND-T study.

Lancet 389, 1206–1217, 2017

Tanaka K, Okada Y, Mori H, Inada Y, Suzuka K, Uriu K, Tanaka Y.

Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease. Assessment by continuous glucose monitoring—a pilot study—.

Diabetology International 64: 179–189, 2017

Torimoto K, Okada Y, Sugino S, Tanaka Y.

Determinants of hemoglobin A1c level in patients with type 2 diabetes after in-hospital diabetes education: A study based on continuous glucose monitoring.

J Diabetes Invest 8: 314–320, 2017

Takeuchi T, Nakajima R, Komatsu S, Yamazaki K, Nakamura T, Agata N, Igarashi A, Tango T, Tanaka Y.

Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUEAU study.

Adv Ther 34: 686–702, 2017

Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y.

Abatacept therapy reduces CD28⁺CXCR5⁺ follicular helper like T cells in patients with rheumatoid arthritis.

Clin Exp Rheumatol 35: 562–570, 2017

Mori H, Okada Y, Tanaka Y.

Effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus.

Internal Medicine 56: 1301–1306, 2017

Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KI, Charles-Schoeman C,

Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Ann Rheum Dis 76: 1253–1262, 2017

Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Wada A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T.

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study,a phase III randomized trial.

Ann Rheum Dis 76: 1348–1356, 2017

Torigoe M, Iwata S, Nakayamada S, Sakata K, Zhang M, Hajime M, Miyazaki Y, Narisawa M, Ishii K, Shibata H, Tanaka Y.

Metabolic reprogramming commits differentiation of human CD27⁺IgD⁺ B cells to plasmablasts or CD27⁻IgD⁻ Cells.

J Immunol 199: 425–434, 2017

Miyagawa I, Nakayamada S, Nakano K, Yamagata K, Sakata K, Yamaoka K, Tanaka Y.

Induction of regulatory T cells and its regulation with insulin-like growth factor/insulin-like growth factor binding protein-4 by human mesenchymal stem cells.

J Immunol 199: 1616–1625, 2017

Kubo S, Yamaoka K, Amano K, Ngano S, Tohma S, Suematsu E, Nagasawa H, Iwata K, Tanaka Y.

Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: A prospective, multicenter, observational study.

Rheumatology 56, 1293–1301, 2017

Oba K, Horie N, Sato N, Saito K, Takeuchi T, Mimori T, Miyasaka N, Koike T, Tanaka Y.

Remission induction by Raising the dose of remicade in RA (RRRR) study: rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis.

Contemporary Clinical Trials Communications 8, 49–54, 2017

Masaki Y, Matsui S, Saeki T, Tsuboi H, Hirata S, Izumi Y, Miyashita T, Fujikawa K, Dobashi H, Susaki K, Morimoto H, Takagi K, Kawano M, Origuchi T, Wada Y, Takahashi N, Horikoshi M, Ogishima H, Suzuki Y, Kawanami T, Kawanami HI, Sakai T, Fujita Y, Fukushima T, Saito M, Suzuki R, Morikawa Y, Yoshino T, Nakamura S, Kojima M, Kurose N, Sato Y, Tanaka Y, Sugai S, Sumida T.

A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease.

Mod Rheumatol 27, 849–854, 2017

Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L,

Mendelsohn AM, Fan H, Chen C, Bananis E.

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.

Arthritis Rheum 69, 1960–1968, 2017

Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, Iwata S, Miyagawa I, Saito K, Tanaka Y.

Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients.

Arthritis Rheum 69, 2029–2037, 2017

Torimoto K, Okada Y, Koikawa K, Tanaka Y.

Early Effects of Sodium–Glucose Co–Transporter 2 Inhibitors in Type 2 Diabetes: Study Based on

Continuous Glucose Monitoring.

Diabetology & Metabolic Syndrome 9: 60, 2017

Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y.

Anti-PD-1 antibody therapy induces Hashimoto's disease with increase in peripheral blood follicular helper T cells.

Thyroid 27, 1335–1336, 2017

Miyata M, Kakeda S, Iwata S, Nakayamada S, Ide S, Watanabe K, Moriya J, Tanaka Y, Korogi Y.

Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus.

Sci Rep 7: 12566, 2017

Tsuboi H, Hagiwara s, Asashima H, Takahashi H, Hirota T, Noma H, Umehara H, Kawasami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriya M, Takeuchi T, Tanaka Y, Hirata S, Minori T, Matsumoto I, Sumida T.

Comparison of performance of the 2016 ACR–EULAR classification criteria for primary Sjogren's syndrome with other sets of criteria in Japanese patients.

Ann Rheum Dis 76: 1980–1985, 2017

Sakamoto Y, Yamamoto T, Sugano N, Takahashi D, Watanabe T, Atsumi T, Nakamura J, Hasegawa Y, Akashi K, Narita I, Miyamoto T, Takeuchi T, Ikari K, Amano K, Fujie A, Kubo T, Tada Y, Kaneuji A, Nakamura H, Miyamura T, Kabata T, Yamaji K, Okawa T, Sudo A, Ohzono K, Tanaka Y, Yasunaga Y, Matsuda S, Imai Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head, Akiyama M, Kubo M, Kamatani Y, Iwamoto Y, Ikegawa S.

Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head

Sci Rep. 2017 Nov 8;7(1), 2017

Tsujiimura S, Adachi T, Saito K, Tanaka Y.

Role of P-glycoprotein on CD69+CD4+ cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy.

RMD Open. 2017 Jul 14;3(1), 2017

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, de Bono S, Arora V, Linetzky B, Weinblatt ME.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis.

Ann Rheum Dis 76, 1853–1861, 2017

Tanaka Y.

Introducing the launch of Modern Rheumatology Case Reports.

Ishikawa Y, Miyagawa I, Nakano K, Satoh Y, Todoroki Y, Kubo S, Nawata A, Nakayamada S, Saito K, Tanaka Y.

The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different etiology: Report of three cases.

Mod Rheumatol Case Reports 1: 108–112, 2017

田中良哉

関節リウマチの薬物療法

医学と薬学(2017)74, 19–28

田中良哉

関節リウマチへの早期積極的治療介入と treatment holiday

CLINICIAN(2017) 654, 62–67

中野和久、田中良哉

関節リウマチ滑膜におけるDNAメチル化とTET分子

Keynote RA (2017) 5, 9–13

中山田真吾、田中良哉

全身性エリテマトーデスにおける免疫異常のオーバービュー

炎症と免疫 (2017) 25, 120–124

田中良哉

バイオシミラーの現状

Mebio (2017) 34, 54–61

田中良哉

ステロイド性骨粗鬆症

腎と骨代謝 (2017) 30, 123–128

久保智史、中山田真吾、田中良哉

関節リウマチ治療におけるバリシチニブの有用性

リウマチ科 (2017) 57, 410–415

田中良哉

日本のリウマチ学が世界に評価されつづけるには

臨床リウマチ (2017) 29, 1–4

田中良哉

関節リウマチに対する分子標的薬の新展開

臨床免疫・アレルギー科 (2017) 68, 64-71

田中良哉

ステロイドの副作用管理のポイント

臨床と研究 (2017) 94, 855-858

田中良哉

Multi-biomarker disease activity (MBDA)は関節リウマチの疾患活動性を正確に反映するか

リウマチ科 (2017) 58, 63-68

田中良哉.

骨髓由来間葉系幹細胞を用いた骨関節疾患治療

THE BONE (2017) 31, 211-216

久保智史、田中良哉

CORRONA レジストリーのアバタセプトとトリソラズマブのcomprative effectiveness study

リウマチ科 (2017) 58, 441-445

中山田真吾、田中良哉

JAK 阻害薬の開発の現状と今後の展望

リウマチ科 (2017) 58, 452-560

田中良哉

期待される血管炎の新規治療

呼吸器内科 (2017) 32, 375-379

中山田真吾、田中良哉

バリシチニブ

分子リウマチ治療 (2017) 10, 197-201

久保智史、田中良哉

関節の MRI の診かた

分子リウマチ治療 (2017) 47, 1089-1093

田中良哉

JAK 研究 UPDATE: JAK 阻害薬に迫る

Joint and Kinase Frontier (2017) 1, 2-3

田中良哉

ステロイド過剰と骨リモデリング異常

CLINICAL CALCIUM (2017) 27, 1731–1738

田中良哉

バイオシミラーの開発の現状と未来

リウマチ科 (2017) 58, 607–613

Kawabe A, Tsujimura S, Saito K, Tanaka Y.

Successful switch to golimumab for eosinophilia and skin symptoms related to multiple biologics in a patient with rheumatoid arthritis.

Internal Med (2017) 56: 1575–158

Yoshinari H, Saito K, Nakano K, Fukuyo S, Miyagawa I, Tanaka Y.

A case of rheumatoid arthritis treated with infliximab who developed disseminated *Penicillium marneffei* infection after visit to Thailand.

Mod Rheumatol Case Reports (2017) 1, 43–48

Kawabe A, Nakano K, Aiko Y, Aramaki S, Onoue T, Okura D, Tanaka Y.

Successful management of pregnancy in a patient with systemic lupus erythematosus-associated pulmonary arterial hypertension.

Internal Med (2017) 56, 1575–1580

Arao T, Okada Y, Torimoto K, Sugai K, Otsuka T, Kurozumi A, Tanaka Y.

Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Metformin/Calcium Channel Blocker/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes.

J UOEH (2017) 39: 1–9

Arao T, Okada Y, Uemura F, Nishizawa S, Tanaka Y.

A Case of Acromegaly in which a Pituitary Gland Tumor was Reduced Significantly by Administering Octreotide Long Acting Release (LAR) and Could Be Removed Surgically.

J UOEH (2017) 39: 241–245

Torimoto K, Okada Y, Kurozumi A, Narisawa M, Arao T, Tanaka Y.

Features of Patients with Basedow's Disease and High Serum IgG4 Levels.

Internal Med (2017) 56, 1009–1013

Kawabe A, Tsujimura S, Saito K, Tanaka Y.

Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis.

Nakano K, Aritomi T, Okubo N, Tanaka Y.

Relapsing polychondritis diagnosed by fusion images of gallium-67 on single photon emission computed tomography/computed tomography.

Arthritis Rheum (2017) 69, 2406

新生忠司、岡田洋右、須貝慧、鳥本桂一、田中良哉

シタグリプチン 50mg からミチグリニド/ボグリボース配合錠への変更が有用であった 2 型糖尿病の1例

CALM (2017) 4, 71–73

五嶋由紀子、岡田洋右、鳥本桂一、田中良哉

リラグルチドのインスリン併用療法における有効性および安全性の検討

Diabetes Frontier (2017) 28, 1–4

新生忠司、岡田洋右、上村美美、西澤茂、田中良哉

オクレオチド Long Acting Release (LAR)投与により下垂体腫瘍が著明に縮小し治癒切除し得た先端巨大症の1例

J UOEH (2017) 39, 241–245

大塚隆史、岡田洋右、新生忠司、田中健一、田中良哉

腰痛を契機に甲状腺クリーゼを発見できた高齢者 Basedow 病の1例

内科 (2017) 120: 1006–1009

井上嘉乃、中野和久、宮崎佑介、中山田真吾、福與俊介、久保智史、宮川一平、斎藤和義、田中良哉

治療抵抗性の関節リウマチ(RA)と全身性エリテマトーデス(SLE)の併発に対しリツキシマブ(RTX)投与にて疾患活動性を制御できた 1 例

九州リウマチ (2017) 37, 112–117

新生忠司、岡田洋右、成澤学、鳥本桂一、田中良哉

重症成人成長ホルモン分泌不全症における成長ホルモン補充療法による治療 1 年後の当体者への影響に関する検討

Diabetes Frontier (2017) 28, 594–598

平成30年(2018年)

Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S.

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus.

Clinical Immunology (2018) 186: 21–25

Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T.
A Therapeutic Target for Bone Destruction in Rheumatoid Arthritis
Mod Rheumatol (2018) 28, 9–16

Yamagata K, Nakayamada S, Tanaka Y.
Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair.
Inflammation and Regeneration (2018) 38: 4, doi.org/10.1186/s41232-018-0061-1

Miyagawa I, Nakayamada S, Kondo M, Tanaka Y.
Regulatory mechanism of the induction of regulatory T cells through growth factors released by human mesenchymal stem cells.
Critical Reviews in Immunology (2018) 38:471–478

Tanaka Y, Ohira T.
Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK–RANKL system.
Curr Opin Pharmacol (2018) 40, 110–119

Tanaka Y, Ishii T, Cai Z, Schlichting D, Rooney T, Macias W.
Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52 week, randomized, single-blind, extension study.
Mod Rheumatol 28, 20–29, 2018

Tanaka Y, Yamazaki K, Nakajima R, Komatsu S, Igarashi A, Tango T, Takeuchi T.
Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
Mod Rheumatol 28, 39–47, 2018

Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago E, Kawakubo M, Kitahara Y, Hojo S, Kawano T, Imai T.
Safety, pharmacokinetics, and efficacy of E6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.
Mod Rheumatol 28, 58–65, 2018

Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S and the SHINOBI study group.
A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Subcutaneous Tocilizumab Every Other Week: Results of the 12-Week Double-Blind Period.
Mod Rheumatol 28, 76–84, 2018

Yamanaka H, Kishimoto M, Pappas DA, Greenberg JD, Kremer JM, Tanaka Y.
Design characteristics of the Corrona Japan rheumatoid arthritis registry.
Mod Rheumatol 28, 95–100, 2018

Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, Miyagawa I, Hirata S, Nakano S, Saito K, Tanaka Y.

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.

Rheumatology 57, 164–174, 2018

Zhang F, Bae S, Bass D, Chu M, Egginton s, Gordon D, Roth D, Zheng J, Tanaka Y.

A pivotal Phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.

Ann Rheum Dis 77, 355–363, 2018

Uemura F, Okada Y, Torimoto K, Tanaka Y.

Relation between hypoglycemia and glycemic variability in type 2 diabetes patients with insulin therapy: A study based on continuous glucose monitoring.

Diabetes Technology and Therapeutics 20, 140–146, 2018

Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N.

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).

Ann Rheum Dis 77, 348–354, 2018

Hajime M, Okada Y, Mori H, Otsuka T, Kawaguchi M, Miyazaki M, Kuno F, Sugai K, Sonoda S, Tanaka K, Kurozumi A, Narisawa M, Torimoto K, Arao T, Tanaka Y.

24-hour variations in blood glucose level in type 2 diabetic Japanese based on continuous glucose monitoring.
J Diabetes Invest 9, 75–82, 2018

Kurozumi A, Okada Y, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus.
J Diabetes Invest 9: 360–365, 2018

Kurozumi A, Okada Y, Sugai K, Torimoto K, Tanaka Y.

Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.

J UOEH 40: 1–9, 2018

Sonoda S, Okada Y, Mori H, Uemura F, Sugai K, Hajime M, Tanaka K, Kurozumi A, Narisawa M, Torimoto K, Tanaka Y.

Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring.

J UOEH 40: 11–18, 2018

Tsujiimura S, Adachi T, Saito K, Kawabe A, Tanaka Y.

Relevance of P-glycoprotein on CXCR4⁺ B cells to organ manifestation in highly active rheumatoid arthritis.

Mod Rheumatol 28: 276–28, 2018

Kubo S, Nakayamada S, Zhao J, Yoshikawa M, Miyazaki Y, Nawata A, Hirata S, Nakano K, Saito K, Tanaka Y.

Correlation of T follicular helper cells and plasmablast with the development of organ involvement in patients with IgG4-related disease.

Rheumatology 57: 514–524, 2018

Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, Tanaka Y.

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: A randomized phase 3 safety and efficacy study in Japanese patients.

Arthritis Res Ther 20: 42, 2018

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RC, Chinoy H, Rothwell S, Lamb JA, Vencovský J, Mann H, Ohmura K, Myouze K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawakami H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K.

Splicing variant of WDFY4 augments MDA5 signaling and the risk of clinically amyopathic dermatomyositis.

Ann Rheum Dis 77: 602–611, 2018

Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, Saito K, Tanaka Y.

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.

Clin Immunol 191: 67–74, 2018

Kakugawa T, Sakamoto N, Ishimoto h, Shumizy T, Nakamura H, Nawata A, Itoi C, Sato S, Hanaka T, Oda K, Kido T, Miyamyra T, Nakashima S, Aoki T, Nakashima S, Obase Y, Saito K, Yatera K, Ishimoto Y, Nakayama T, Korogi Y, Kawakami A, Tanaka Y, Mukae H.

Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome.

Respiratory Medicine 137, 95–102, 2018

Sonoda S, Yoshimura M, Abe C, Morita H, Ueno H, Motojima Y, Saito R, Maruyama T, Hashimoto H, Tanaka Y, Ueta Y.

Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs.

Peptides 105, 14–20, 2018

Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y.

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.

Lupus 27: 802–811, 2018

Gudmann N, Hirata S, Karsdal M, Bay-Jensen A, Tanaka Y.

Increased remodeling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: a one year prospective study.

Clin Exp Rheumatol 36:462–470, 2018

Nawata A, Hisano S, Shumarjir S, Wang KY, Tanaka Y, Nakayama T.

Podocyte and endothelial cell injury develop nephrotic syndrome in proliferative lupus nephritis.

Histopathology 72: 1084–1092, 2018

Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada S, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibaa M, Goto H, Sato Y, Yoshida T, Mimori T.

Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study

Science Reports 8:10262, 2018

Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dorner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, do Bono S, Silk ME, Hoffman RW.

Baricitinib for Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study.

Lancet 392: 222–231, 2018

Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, Tamura N, Fujio K, Fujii T, Kojima T, Anzai T, Hamada C, Fujino Y, Matsuda S, Kohsaka H.

Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC Study.

Arthritis Res Ther 20: 151, 2018

Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma XX, Lee SH, Ishii A, Yamagata K, Nakano K, Tanaka Y.
Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.
Front Immunol 9: 1510, 2018

Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T.

Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study

Int J Rheum Dis 21: 1609-1618, 2018

Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, Yoshikawa M, Kitanaga Y, Zhang M, Tanaka Y.

Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.

Ann Rheum Dis 77: 1354-1361, 2018

Kaneko Y, Kato M, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T, and the SURPRISE study group. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).

Ann Rheum Dis 77: 1268-1275, 2018

Torimoto K, Okada Y, Hajime M, Tanaka K, Tanaka Y.

Risk factors of hypoglycaemia in patients with type 2 diabetes mellitus: A study based on continuous glucose monitoring.

Diabetes Technol Ther 20: 603-612, 2018

Tanaka Y, McInnes IB, Taylor PC, Byers NNL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P.

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis.

Arthritis Rheum 70, 1932-1932, 2018

Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Ukyo Y, Ishii Y, Yoshinari T, Baker D, and the GO-MONO study group.

Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.

Mod Rheumatol 28, 770-779, 2018

Tanaka Y, Atsumi T, Amano K, Harigai M, Ishii T, Kawaguchi O, Rooney TP, Akashi N, Takeuchi T.
Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Mod Rheumatol 28, 583–591, 2018

Takeuchi T, Tanaka Y, Yamanaka h, Harigai M, Nakano T, Akagi K, Ukyo Y, Hsu B.
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.
Mod Rheumatol 28, 941–949, 2018

Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshinara T, Suzuki Y, Kawano M, Tomiita M, Tsuboi H.

Clinical practice guideline for Sjögren's syndrome 2017
Mod Rheumatol 28, 383–408, 2018

Tuttle KR, Brosius III FC, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.
JAK1/JAK2 Inhibition by Baricitinib in Diabetic Kidney Disease: Results from a Phase 2 Randomized Controlled Clinical Trial.

Nephrology Dialysis Transplantation 33: 1950–1959, 2018

Ide S, KakedaS, Miyata M, Iwata S, Ohkubo N, Nakayamada s, Tutqatsuya K, Watanabe K, Moriya J, Tanaka Y, Korogi Y.

Intracranial vessel wall lesions in patients with systematic lupus erythematosus.
J Magn Reson Imaging 48: 1237–1246, 2018

Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Nakano K, Tanaka Y.
Up-regulation of TLR7-mediated IFN- β production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus.
Front Immunol Aug 28;9:1957, 2018

Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T.
Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Ann Rheum Dis 77, 1720–1729, 2018

Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T.

Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study

Int J Rheum Dis 21: 1609–1618, 2018

Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Yamagata K, Hirata S, Sakata K, Todoroki Y, Nakano K, Nakayamada S, Satoh M, Tanaka Y.

Relevance of IFN- γ in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.

Arthritis Res Ther Oct 26;20(1):240, 2018

Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y.

Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.

Clin Immunol Oct;195:1–7, 2018

Mori H, Okada Y, Kawaguchi M, Otsuka T, Miyazaki M, Sonoda S, Sugai K, Uemura F, Tanaka K, Hajime M, Kurozumi A, Narisawa M, Torimoto K, Tanaka Y.

Profiling in patients with drug-naïve type 2 diabetes by continuous glucose monitoring.

J UOEH. 2018; 40: 287–297, 2018

Matsubara T, Inoue H, Nakajima T, Tanimura K, Sagawa A, Sato Y, Osano K, Nagano s, Ueki Y, Hanyu T, Hashizume K, Amano N, Tanaka Y, Takeuchi T.

Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study.

RMD Open. 4 (2) , 2018

Miyazaki Y, Nakayamada S, Kubo S, Nakano K, Iwata S, Miyagawa I, Ma X, Trimova G, Sakata K, Tanaka Y. Th22 cells promote osteoclast differentiation via production of IL-22.

Front Immunol Dec 10;9:2901, 2018

Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H.

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.

Mod Rheumatol 28: 986–992, 2018

Mori H, Okada Y, Kawaguchi M, Otsuka T, Miyazaki M, Sonoda S, Sugai K, Uemura F, Tanaka K, Hajime M, Kurozumi A, Narisawa M, Torimoto K, Tanaka Y.

Glycemic Profiling in Patients with Drug-Naïve Type 2 Diabetes by Continuous Glucose Monitoring.

J UOEH 40: 287–297, 2018

Yamagata K, Nakayamada S, Tanaka Y.

Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair.

Inflammation and Regeneration 38, 4, 2018

Terao C, Yoshifiji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F.

Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis.

Proc Natl Acad Sci U S A. 115, 13045–13050, 2018

Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T.

Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC).

Mod Rheumatol 28, 642–648, 2018

Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y.

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.

Lupus 27, 1202–1206, 2018

Nagayasu A, Kubo S, Nakano K, Nakayamada S, Iwata S, Miyagawa I, Fukuyo S, Saito K, Tanaka Y.

IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion: A Case Report.

Intern Med 57, 2251–2257, 2018

Ohkubo N, Nakano K, Miyagawa I, Iwata S, Fukuyo S, Kubo S, Tamaki Y, Nakayamada S, Tanaka Y.

Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus.

Mod Rheumatol Case Rep 2, 137–142, 2018

田中良哉, 渥美達也, 山本一彦, 竹内勤, 山中寿, 石黒直樹, 江口勝美, 渡辺彰, 折笠秀樹, 小路利治, P. Ralston, 宮坂信之, 小池隆夫

メトトレキサート未治療早期関節リウマチ患者に対する予後不良因子の検討とセルトリズマブペゴルの有効性の検討:無作為化, プラセボ対照第三相, C-OPERA 試験のサブグループ解析

久保智史、田中良哉
強皮症
リウマチ科 (2018) 59, 27–32

田中良哉
ステロイド性骨粗鬆症
日本医師会雑誌 (2018) 146, 2045–2048

田中良哉、遠藤直人、杉本利嗣、伊東昌子
ミネラル代謝研究・臨床における国内外の動向
THE BONE (2018) 31, 441–448

田中良哉
関節リウマチの治療法の進歩
CLINICAL CALCIUM (2018) 28, 395–401

鳥本桂一、岡田洋右、田中良哉
2型糖尿病と血管内皮機能障害
産業医科大学雑誌 (2018) 40: 65–75

田中良哉
関節リウマチの治療における骨吸収抑制薬
CLINICAL CALCIUM (2018) 28, 630–636

中山田真吾、田中良哉
関節リウマチ治療に伴う免疫フェノタイプの変化
CLINICAL CALCIUM (2018) 28, 619–625

田中良哉
ビタミン D が免疫機能に与える影響
食と医療 (2018) 5, 28–35

中山田真吾、田中良哉
膠原病に対する新規分子標的療法
Medical Practice (2018) 35, 955–959

田中良哉
バイオシミラーの使い方

リウマチ科 (2018) 59, 616–621

福輿俊介、中野和久、田中良哉
RA に対するバイオシミラーの進歩
リウマチ科 (2018) 60, 90–96

田中良哉
アクセプトされやすい英文論文の書き方
臨床リウマチ (2018) 30, 12–14

宮崎佑介、中野和久、田中良哉
セルトリズマブ ペゴル
分子リウマチ治療 (2018) 22, 132–136

田中良哉
米国リウマチ学会のステロイド性骨粗鬆症の予防と治療のガイドライン(2017年版)
リウマチ科 (2018) 60, 188–193

田中良哉
JAK 阻害薬は新たなパラダイムシフトをもたらすか?
Joint and Kinase Frontier (2018) 2, 2–5

田中良哉
内科疾患における生物学的製剤の使い分け
Modern Physician (2018) 38, 915–916

岩田慈、田中良哉
リツキシマブ
Modern Physician (2018) 38, 956–958

久保智史、田中良哉
ベリムマブ
Modern Physician (2018) 38, 959–961

久保智史、田中良哉
RA 疾患活動性制御後のトファシチニブ休薬について
リウマチ科 (2018) 60, 280–284

田中良哉
バリシチニブ

炎症と免疫 (2018) 26, 520–525

宮川一平、田中良哉.

リウマチ医から見た乾癬性関節炎と生物学的製剤を用いた precision medicine
CLINICIAN (2018) 668, 37–43

田中良哉

ステロイド性骨粗鬆症の診断と治療

Medical Practice (2018) 35, 1712–1724

田中良哉

関節リウマチにおける骨障害と骨粗鬆症の病態

分子リウマチ治療 (2018) 11, 172–176

田中良哉

関節リウマチ

PharmaTribune (2018) 100, 20–25

中野和久、岡田洋右、田中良哉

関節リウマチにおける骨代謝異常

Clinical Calcium (2018) 33, 1599–1603

Otsuka T, Okada Y, Torimoto K, Tanaka Y.

Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance.

Internal Med (2018) 57: 2923–2927

Tanaka K, Okada Y, Mori H, Torimoto K, Arao T, Tanaka Y.

Effects of metformin and repaglinide on postprandial hyperglycemia in patients on methylprednisolone pulse therapy.

Internal Med (2018) 57, 65–70

Koikawa K, Okada Y, Mori H, Kawaguchi M, Uchino S, Tanaka Y.

A case of hyperparathyroidism–jaw tumor syndrome confirmed by preoperative genetic testing.

Internal Med (2018) 57, 841–844

Kawabe A, Nakano K, Aiko Y, Aramaki S, Onoue T, Okura D, Tanaka Y.

Successful management of pregnancy in a patient with systemic lupus erythematosus–associated pulmonary arterial hypertension.

Internal Med (2018) 57: 1655–1659

轟泰幸、久保智史、中野和久、中山田真吾、岩田慈、福興俊介、宮川一平、名和田彩、田中良哉
リツキシマブが奏効したオーバーラップ症候群(全身性エリテマトーデス・関節リウマチ・全身性強皮症)の一例
九州リウマチ (2018) 38, 118-123

上野匡庸、中野和久、宮川一平、中山田真吾、岩田慈、福興俊介、久保智史、宮崎佑介、河邊明男、田中良哉

上大静脈症候群を呈した血管型ベーチェット病の1例
九州リウマチ (2018) 381, 124-129

永安敦、中野和久、宮川一平、中山田真吾、岩田慈、福興俊介、久保智史、田中良哉
外転神経麻痺で発症した好酸球性多発血管炎性肉芽腫症の一例
九州リウマチ (2018) 38, 130-137

有富貴史、中野和久、宮川一平、玉城泰太郎、宮田寛子、岩田慈、福興俊介、中山田真吾、田中良哉
消化管潰瘍を反復した骨髄異形成症候群関連結節性多発動脈炎の1例
九州リウマチ (2018) 38, 138-144

上野匡庸、中野和久、吉成紘子、中山田真吾、久保智史、宮川一平、好川真以子、田村雅仁、宮本哲、齋藤和義、田中良哉
MPO-ANCA陽性を呈した抗GBM抗体型腎炎の1例
九州リウマチ (2018) 38, 57-62

上村英美、岡田洋右、鳥本桂一、田中良哉
甲状腺機能亢進症治療前後での食後過血糖の改善をCGMで確認したバセドウ病の1例
Diabetes J (2018) 46, 24-29

新生忠司、岡田洋右、鳥本桂一、大塚隆史、田中良哉
体重増加後も無自覚性低血糖が遷延した神経性食思不振症の1例
糖尿病 (2018) 61, 833-839

平成31・令和2年(2019年)

Tanaka Y.

The JAK inhibitors: Do they bring a paradigm shift for the management of rheumatic diseases?
Rheumatology 58, i1-i3, 2019

Tanaka Y:

Clinical immunity in bone and joints.

J Bone Miner Metabolism 37, 2–8, 2019

Kubo S, Nakayamada S, Tanaka Y

Immunophenotype involved in IgG4-related disease.

Mod Rheumatol 29, 226–230, 2019

Umeshara H, Okazaki K, Kawano M, Tanaka Y

The front line of research into immunoglobulin (Ig) G4-related disease – Do autoantibodies cause IgG4-RD?

Mod Rheumatol 29, 214–218, 2019

Miyagawa I, Nakayamada S, Tanaka Y

Optimal biologic selection for treatment of psoriatic arthritis: the approach to precision medicine

Current Rheumatolgy Report 21, 21, 2019

Kubo S, Smith V, Cutolo M, Tanaka Y

The role of nailfold videocapillaroscopy in patients with systemic sclerosis

Immunol Med 41, 113–119, 2019

Tanaka Y, Kubo S, Miyagawa I, Iwata S, Nakayamada S.

Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases.

Semin Arthritis Rheum 48, 1146–1150, 2019

Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kakubo M, Torii K, Hojo S, Kawano T, Imai T.

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis.

European Medical Journal Rheumatology 6, 71–73, 2019

Kubo S, Nakayamada S, Tanaka Y.

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update

Expert Rev Clin Immunol 15, 693–700, 2019

Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh M, Nawata A, Miyagawa I, Saito K, Smith V, Cutolo M, Tanaka Y.

Significance of nailfold videocapillaroscopy in patients with Idiopathic inflammatory myopathies.

Rheumatology 58: 120–130, 2019

Tanaka Y, Sugiyama N, Toyoizumi S, Lukic T, Lamba M, Zhang R, Chen C, Stock T, Valdez H, Mojckik C, Fan H, Deng C, Yuasa H.

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomised, phase III, non-inferiority study.

Rheumatology 58: 70–79, 2019

Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, Yoshikawa M, Yoshinari H, Tanaka Y. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.

Rheumatology 58: 336–344, 2019

Torimoto K, Okada Y, Tanaka Y, Matsuoka A, Hirota Y, Ogawa W, Saisho Y, Kurihara I, Inada S, Koga M. Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study.

BMC Cancer 19: 174, 2019

Yoshikawa M, Nakayamada S, Kubo S, Nawata A, Kitanaga Y, Iwata S, Sakata K, Ma X, Wang S, Nakano K, Saito K, Tanaka Y.

Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.

Clin Immunol 200: 1–9, 2019

Hajime M, Okada Y, Mori H, Uemura F, Sonoda S, Tanaka K, Kurozumi A, Narisawa M, Torimoto K, Tanaka Y.

Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. Diabetol Metab Syndr. 11: 18, 2019

Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, Ukyo Y, Hsu B.

Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).

Mod Rheumatol 29, 306–313, 2019

Tanaka Y, Wada K, Takahashi Y, Hgino O, van Hoogstraten H, Graham NMH, Kameda H.

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.

Arthritis Res Ther 21(1): 79, 2019

Hanaka T, Kido T, Ishimoto H, Oda K, Nawata A, Nakayamada S, Tanaka Y, Yatera K, Mukae H.

Radiological patterns of pulmonary involvement may predict treatment response to rheumatoid arthritis: a retrospective study.

Respiratory Investigation 57: 172–182, 2019

Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Inoue Y, Ueno M, Tanaka Y.
Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.

Int J Rheum Dis 22: 434–442, 2019

Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo S, Jan Wu Y, Li Z, An Y, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O’Neill S, Goldblatt F, Hao1Y, Zhang Z, Al-Saleh J, Khamashta M, Takeuchi T, Tanaka Y, Bae S, Lau CS, Hoi1A, Nikpour M, Morand EF.
Development of the Asia Pacific Lupus Collaboration cohort Running title: APLC cohort

Int J Rheum Dis 22: 425–433, 2019

Mori H, Okada Y, Kawaguchi M, Iwata S, Yoshikawa M, Sonoda S, Sugai K, Tanaka K, Hajime M, Narisawa M, Tanaka Y.

Study of vascular endothelial function in patients with type 2 diabetes mellitus and rheumatoid arthritis.

Internal Medicine 58, 1383–1390, 2019

Nakagawa H, Tanaka Y, Sano S, Kameda H, Taniguchi A, Kashiwagi T, Kawaberi T, Kimura J, Morita A.

Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis.

Advances in Therapy 36: 691–707, 2019

Sonoda S, Yoshimura M, Abe C, Morita H, Ueno H, Motojima Y, Saito R, Maruyama T, Hashimoto H, Tanaka Y, Ueta Y.

Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia.

Neuropeptides 75: 34–40, 2019

Tanaka Y, Bass D, Chu M, Egginto S, Ji b, Struemper H.

Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a Phase 3 randomized placebo-controlled trial.

Mod Rheumatol 29: 452–460, 2019

Ishiguro N, Tanaka Y, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D, Takeuchi T.

Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.

Rheumatology 58, 997–1005, 2019

Torimoto K, Okada Y, Tanaka Y.

Hypoglycemia abrogates the vascular endothelial protective effect of exenatide in type 2 diabetes mellitus.
Diabetes Therapy 10, 1127–1132, 2019

van der Heijde D, Schiff M, Tanaka Y, Xie Li, Meszaroos G, Ishii T, Casillas M, Ortmann R, Emery P.
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.

RMD Open 5 (1) , 2019

Kurozumi A, Nakano K, Yamagata K, Okada Y, Nakayamada S, Tanaka Y.
IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2.
Bone 124, 53–61, 2019

Smolen JS, Pangan AL, Emery P, Eigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S.
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Lancet 393, 2303–2311, 2019

Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D.
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying anti-rheumatic drugs (DESIRABLE study): a randomized, double-blind, placebo-controlled phase 3 trial.
Ann Rheum Dis 78, 899–907, 2019

Tanaka Y, Fautrel b, Keystone E, Ortmann R, Xie L, Zhu B, Issa M, Patel H, Gaich C, de Bono S, Rooney T, Taylor PC.
Clinical outcomes in patients switched from adalimumab to baricitinib due to nonresponse and/or study design: phase III data in patients with rheumatoid arthritis.
Ann Rheum Dis 78: 890–898, 2019

van der Heijde, D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardeil MH, Cohen S, Nash P, Song Y, Tegzova D, Gruben D, Wallenstein G, Connel CA, Fleischmann R and the ORAL Scan investigatory. Tofacitinib plus methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic and safety outcomes through 24 months.
Arthritis Rheum 71, 878–891, 2019

Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y.

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero–Behcet’s disease.

Arthritis Res Ther 21: 151, 2019

Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P.

Patients achieving sustained deep remission, deep remission or sustained remission of rheumatoid arthritis are more likely than other responders to maintain remission or low disease activity after dose reduction or withdrawal of etanercept.

Arthritis Res Ther 21: 164, 2019

Kurozumi A, Okada Y, Shimokawa M, Goshima Y, Otsuka T, Narisawa M, Torimoto K, Tanaka Y.

Efficacy and Safety of Tofogliflozin on 24-H Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium–Glucose Cotransporter 2 Inhibitor.

Diabetes Technol Ther 21: 385–392, 2019

Lee EB, Yamanaka H, Liu Y, Tsai WC, Chen C, Kwok K, Yoo HJ, Llamado LJ, Wang L, Lou Y, Sugiyama N, Tanaka Y.

Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia–Pacific region: post-hoc analyses of pooled clinical study data.

Int J Rheum Dis 22, 1094–1106, 2019

Okabe Y, Aoki T, Terasawa T, Kinoshita S, Nakayamada S, Tanaka Y, Korogi Y.

Mediastinal and axillary lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance.

Clin Imaging 55, 140–143, 2019

Tanaka Y, Mimori T, Yamanaka H, Nakajima R, Morita K, Kimura J, Takeuchi T.

Effectiveness and safety of initiating adalimumab plus ≥ 12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan.

Mod Rheumatol 29, 572–580, 2019

Miyata M, Kakeda S, Kubo K, Iwata S, Tanaka Y, Wang Y, Korogi Y.

Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping.

J Cereb Blood Flow Metab 39: 1648–1658, 2019

Torimoto K, Okada Y, Hoshima Y, Tokutsu A, Sato Y, Tanaka Y.

Addition of canagliflozin to insulin improves glycemic control and reduces insulin dose in patients with type 2 diabetes mellitus: a randomized controlled trial.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Díaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Ann Rheum Dis 78, 1151–1159, 2019

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Díaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Arthritis Rheumatol 71, 1400–1412, 2019

Terao C, Ota M, Iwasaki T, Shiokawa M, Kawaguchi S, Kuriyama K, Kawaguchi T, Kodama Y, Yamaguchi I, Uchida K, Higasa K, Yamamoto M, Kubota K, Yazumi S, Hirano K, Masaki Y, Maguchi H, Origuchi T, Matsui S, Nakazawa T, Shiomi H, Kamisawa T, Hasebe O, Iwasaki E, Inui K, The Japanese IgG4-related disease working consortium, Tanaka Y, Oshima K, Akamizu T, Nakamura S, Nakamura S, Saeki T, Umehara H, Shimosegawa T, Mizuno N, Kawano M, Azumi Am Takahashi H, Mimori T, Kamatani Y, Okazaki K, Chiba T, Kawano S, Matsuda F.

A genome wide study of IgG4-related disease in the Japanese people.

Lancet Rheumatol 1, e14–e22, 2019

Torigoe M, Maeshima K, Ozaki T, Omura Y, Gotoh K, Tanaka Y, Ishii K, Shibata H.

I-Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling.

Mod Rheumatol 29, 885–891, 2019

Ogata A, Tanaka Y, Ishii T, Kaneko M, Miwa H, Ohsawa S, Yamakawa R, the SHINOBI Study Group. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: results from the open-label extension of the SHINOBI study.

Mod Rheumatol 29, 767–774, 2019

Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyozumi S, DeMasi R, Fukuma Y, Hirose T, Sugiyama N, Zwillich SH, Tanaka Y.

Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post-hoc analysis of clinical trial data.

Mod Rheumatol 29, 756–766, 2019

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko K, Shiomi T, Yamada E, van der Heijde D.

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.

Ann Rheum Dis 78, 1305–1319, 2019

Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Song Y, Chen Y, Wei JC, Lee S, Rokuda M, Izutsu H, Ushijima S, Kaneko K, Shiomi T, Yamada E.

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).

Ann Rheum Dis 78, 1320–1332, 2019

Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, Koike T.

Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.

Mod Rheumatol 29: 747–755, 2019

Tsujiura S, Tanaka Y.

Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp⁺CD4⁺ Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis.

Internal Medicine 58, 3173–3178, 2019

Kubo S, Nakayamada S, Miyazaki Y, Yoshikawa M, Yoshinari H, Satoh Y, Todoroki Y, Nakano K, Satoh M, Smith V, Cutolo M, Tanaka Y.

Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis.

Rheumatology 58: 2273–2283, 2019

Tanaka K, Yamagata K, Kubo S, Nakayamada S, Sakata K, Matsui T, Yamagishi S, Okada Y, Tanaka Y.
Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10.

Bone 128: 115034, 2019

Kubo S, Nakayamada S, Tanaka Y.

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Expert Review of Clinical Immunology 15, 693–700, 2019

Gadina M, Li M, Schwartz D, Silvenoinenn O, Nakayamada S, Yamaoka K, O’Shea JJ.

Janus kinases to Jakinibs: from basic insights to clinical practice.

Rheumatology (Oxford) 58: i4–i16, 2019

Ueno M, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Tanaka Y.

An Autopsy Case with Cerebral Hemorrhaging Due to Disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis.

Intern Med 58: 1023–1027, 2019

Satoh Y, Nakano K, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I, Yoshinari H, Satoh M, Tanaka Y.

The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects.

Mod Rheumatol Case Rep 3: 114–118, 2019

Kubo S, Tanaka Y.

Scleroderma in an ice-cream shop worker.

Rheumatology (Oxford) 58, 1120–1121, 2019

中山田真吾、田中良哉

全身性エリテマトーデスの precision medicine

Precision Medicine (2019) 2, 22–25

田中良哉

ステロイド性骨粗鬆症のメカニズム

分子リウマチ治療 (2019) 12, 25–30

田中良哉

Treat to Target の基本的な考え方

THE BONE (2019) 32, 259–262

大久保直紀、河邊明男、中野和久、田中良哉

関節リウマチとエピゲノム修飾

リウマチ科 (2019) 61, 135-141

久保智史、中山田真吾、田中良哉

IL-21 は SLE における自己反応性 CD11c 高発現 T-bet 陽性 B 細胞の増殖と形質細胞分化を促進する

リウマチ科 (2019) 61, 170-174

田中良哉

生物学的製剤による新規治療の展望

日本医事新報 (2019) 4947, 44-49

田中良哉

成人全身性エリテマトーデス

日本臨床 (2019) 77, 420-427

田中良哉

骨と関節の内科学

日本内科学会雑誌 (2019) 108, 104i-111i

中山田真吾、久保智史、田中良哉

生物学的抗リウマチ薬の末梢血免疫細胞プロファイルに対する影響

リウマチ科 (2019) 61, 170-174

宮川一平、田中良哉

乾癬性関節炎に対する生物学的製剤の使いわけ

日本医事新報 (2019) 4951, 40-45

田中良哉

膠原病・リウマチ疾患における抗サイトカイン療法～update～

日本内科学会雑誌 (2019) 108, 393-400

田中良哉

関節リウマチ： 治療薬を使いこなすワザと知恵

薬局 (2019) 70, 1110-1111

中山田真吾、田中良哉

JAK 阻害薬

薬局 (2019) 70, 1143-1151

田中良哉

関節リウマチにおける治療費軽減対策：バイオシミラーとドラッグホリデー
薬局 (2019) 70, 1213-1215

田中良哉.

JAK 阻害薬 UPDATE

九州リウマチ (2019) 39, 1-6

田中良哉.

関節リウマチ

総合リハビリテーション (2019) 47, 483-487

中山田真吾、田中良哉.

ベリムマブ

分子リウマチ治療 (2019) 12, 77-80

田中良哉.

NPSLE の臨床.

BRAIN and NERVE (2019) 71, 445-458

田中良哉

JAK 阻害薬の安全性

Joint and Kinase Frontier (2019) 3, 2-5

中山田真吾、田中良哉.

全身性エリテマトーデス

炎症と免疫 (2019) 27, 305-309

久保智史、田中良哉

JAK 阻害薬による自然免疫および適応免疫に対する作用

リウマチ科 (2019) 62, 6-10

田中良哉

バリシチニブの有効性と安全性

リウマチ科 (2019) 62, 33-40

中山田真吾、田中良哉

関節リウマチ治療における JAK 阻害薬

臨末リウマチ (2019) 31, 162-168

田中良哉
骨粗鬆症関連検査
臨床と研究 (2019) 96, 946–950

田中良哉
リウマチ性疾患の生物学的製剤療法
臨床免疫・アレルギー科 (2019) 72, 242–249

田中良哉
サリルマブの RA 治療.
炎症と免疫 (2019) 27, 417–421

轟泰幸、中野和久、田中良哉
SLE に対するアニフルマブ (anifrolumab)
リウマチ科 (2019) 62, 255–259

佐藤友梨絵、中山田真吾、田中良哉
SLE に対する JAK 阻害療法
リウマチ科 (2019) 62, 266–272

田中良哉
骨と関節の内科学
日本内科学会雑誌 (2019) 108, 1700–1712

田中良哉
関節リウマチ
医学と薬学 (2019) 76, 1393–1402

岩田慈、田中良哉
SLE 末梢血で増殖する CD4 陽性 T 細胞集団は IL-10 とコハク酸により B 細胞をヘルプする
リウマチ科 (2019) 62, 360–365

田中良哉.
関節リウマチの治療と管理.
Geriatric Medicine (2019) 57, 1145–1149

宮川一平、田中良哉
末梢血 T 細胞フェノタイプによる乾癬性関節炎の precision medicine
リウマチ科 (2019) 62, 558–563

田中良哉

関節リウマチ診療における骨代謝マーカーの意義

THE BONE (2019) 33, 185–189

久保智史、田中良哉

T 細胞選択的共刺激調整薬(CTLA4-Ig).

Medical Practice (2019) 36, 1109–1114

Kawabe A, Nakano K, Miyata H, Shibuya R, Matsuyama A, Ogochi T, Tanaka Y.

Fatal chronic active Epstein–Barr virus infection in a patient with rheumatoid arthritis receiving abatacept.

Internal Med (2019) 58: 585–591

Aritomi T, Kido T, Nakano K, Satoh Y, Noguchi S, Jotatsu T, Hanaka T, Satoh M, Tanaka Y, Yatera K.

A Case of a Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1 γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy.

Internal Med (2019) 58: 427–431

Miyazaki M, Okada Y, Torimoto K, Tanaka Y.

A Case of Marine–Lenhart syndrome with predominance of Plummer disease.

J UOEH (2019) 41: 165–170

Fujita Y, Nawata M, Someya K, Saito K, Tanaka Y.

Fifty-two-week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease-modifying antirheumatic drug therapy that was successfully treated with baricitinib.

Case Rep Rheumatol (2019)

Kubo S, Tanaka Y.

Scleroderma in an ice-cream shop worker.

Rheumatology (2019) 58, 1120–1121

日下勝秀、中野和久、吉成紘子、岩田慈、福興俊介、花見健太郎、久保 智史、宮川一平、河邊明男、宮崎佑介、名和田彩、井上嘉乃、上野匡庸、有富貴史、中山田真吾、田中良哉

無症候性 IgG4 関連胆嚢炎を伴った IgG4 関連疾患の一例

九州リウマチ (2019) 39, 62–67

大塚隆史、岡田洋右、鳥本桂一、稻田良郁、鈴鹿佳南子、田中良哉

Streptococcus agalactiae による両側腸腰筋膿瘍を呈した糖尿病の 1 例

糖尿病 (2019) 62, 680–685

令和2年(2020年)

Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, Hirata S, Tanaka E, Yasuoka H, Kaneko Y, Murakmi K, Koga T, Nakano K, Amano K, Ushio K, Atumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsunoda S, Dobashi H, Horie N, Sato N.

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomized controlled trial.

Ann Rheum Dis 79, 94–102, 2020

Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, Tummala R.

Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study.

Mod Rheumatol 30, 101–108, 2020

Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, Atsumi T, Sematsu E, Hayashi N, Wang L, Tummala R.

Safety and tolerability of sifalimumab, an anti-interferon- α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: a multicentre, phase 2, open-label study.

Mod Rheumatol 30, 93–100, 2020

Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R.

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

New Engl J Med 382, 211–221, 2020

Chen YC, Yoo DH, Lee CK, Li KJ, Won JE, Wu WS, Zhong J, Nicolay C, Walls CD, Tanaka Y.

Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.

Int J Rheum Dis 23: 65–73, 2020

Trimova G, Yamagata K, Iwata S, Hirata S, Zhan T, Uemura F, Satoh M, Blin N, Nalayamada S, Maksymowych WP, Tanaka Y.

Tumour necrosis factor alpha promotes secretion of 14–3–3 η by inducing necroptosis in macrophages.

Arthritis Res Ther 22: 24, 2020

Yamanaka H, Kamatani N, Tanaka Y, Hibino T, Drescher E, Sánchez-Bursón J, Rettenbacher M, Bhatia G, Gadve S, Shah C, Bakhle D.

A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis.
Rheumatol Ther 7: 149–163, 2020

Jinnin M, Ohta A, Ishihara S, Amano H, Atusmi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori A, Mimori T, Mimura T, Muro Y, Saon H, Shumizu J, Takeuchi T, Yanaka Y, Yamamoto K, Sumida T, Kohsaka H.

The first external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort

Ann Rheum Dis 79: 387–392, 2020

Ochi S, Saito K, Mizoguchi F, Kato S, Tanaka Y.

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study.

Arthritis Res Ther 22: 41, 2020

Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.

Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: a subgroup analysis from a Phase 3 randomized placebocontrolled trial.

Mod Rheumatol 30: 313–320, 2020

Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa A, Shoji T, Miyasaka N, Koike T.

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.

Int J Rheum Dis 23: 316–324, 2020

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, Okuda M, Izutsu H, Ushijima S, Kaneko Y, Nakashima Y, Shiomi T, Yamada E.

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea and Taiwan.
Arthritis Res Ther 22: 47, 2020

Moridera K, Uchida S, Tanaka S, Menuki K, Utsunomiya H, Yamaoka K, Sonomoto K, Tanaka Y, Sakai A. Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice.

J Orthop Sci. 25: 331–337, 2020

Kameda H, Wada H, Takahashi Y, Hagino O, van Hoogstraten H, Graham NM, Tanaka Y.

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in

active rheumatoid arthritis: a Japan phase 3 trial (HARUKA).

Mod Rheumatol 30: 239–248, 2020

Sugihara T, Hasegawa H, Uchida H, Yoshifiji H, Watanabe Y, Amiya e, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M.

Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.

Arthritis Res Ther 22: 72, 2020

Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Inoue Y, Ueno M, Okubo N, Fujita Y, Tanaka Y.

The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.

Int J Rheum Dis 23, 549–558, 2020

Kubo S, Siebuhr A-S, Bay-Jensen A-C, Juhl P, Karsdal MA, Satoh Y, Todoroki Y, Nakano S, Nakayamada S, Tanaka Y.

Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis.

Int J Rheum Dis 23, 532–539, 2020

Emery P, Tanaka Y, Cardillo T, Schlichting D, Rooney T, Beattie S, Helt C, Smolen JS.

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes patients with rheumatoid arthritis.

Arthritis Res Ther (2020) 22:114. doi: 10.1186/s13075-020-02199-8

Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T.

The development of quality indicators for systemic lupus erythematosus using electronic health data: a modified RAND appropriateness method.

Mod Rheumatol 30: 525–531, 2020

Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Yokota I, Atsumi T, Takeuchi T. Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A post-hoc analysis of the SURPRISE study.

Mod Rheumatol 30: 442–449, 2020

Tanaka Y, Mimori T, Yamanaka H, Sunaga N, Morita K, Kimura J, Takeuchi T.
Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: results of the HAWK postmarketing surveillance study in Japan.
Mod Rheumatol 30: 424–433, 2020

Nakamura T, Satoh-Nakamura T, Nakajima A, Kawanami T, Sakai T, Fujita Y, Iwao H, Miki M, Masaki Y, Okazaki T, Ishigaki Y, Kawano M, Yamada K, Matsui S, Saeki T, Kamisawa T, Yamamoto M, Hamano H, Origuchi T, Hirata S, Tanaka Y, Tsuboi H, Sumida T, Okazaki K, Tanaka M, Chiba T, Mimori T, Umehara H. Impaired expression of innate immunity-related genes in IgG4-related disease (IgG4-RD): A possible mechanism in the pathogenesis of IgG4-RD.

Mod Rheumatol 30: 551–557, 2020

Torimoto K, Okada Y, Tanaka Y, Matsuoka A, Hirota Y, Ogawa W, Saisho Y, Kurihara I, Itoh H, Inada S, Koga M.
Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening.
Endocrine J 67, 509–513, 2020

Kawabe A, Nakano K, Kubo S, Tanaka Y.

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry.
Arthritis Res Ther 22: 136, 2020

Miyazaki Y, Nakayamada S, Kubo S, Ishikawa Y, Yoshikawa M, Sakata K, Iwata S, Miyagawa I, Nakano S, Tanaka Y.
Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Arthritis Res Ther 22: 141, 2020

Ishimaru T, Fujino Y, Anzai T, Matsuda S, Tanaka Y.

Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: a multicenter prospective study.

Mod Rheumatol doi: 10.1080/14397595.2019.1661593. Online ahead of print

Strand V, van der Heijde D, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song Y, Tegzoba D, Gruben D, Wallenstein G, Connell CA, Fleischmann R, ORAL Scan investigators. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient reported outcomes from the 24-month Phase 3 ORAL Scan study.
Clin Exp Rheumatol, Online ahead of print

Kitanaga Y, Imamura E, Nakahara Y, Fukahori H, Fujii Y, Kubo S, Nakayamada S, Tanaka Y.
In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Rheumatology 59, 1957–1968, 2020

Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno s, Yoshifuji H, Sakata Y, Kawakami a, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, okada N, Yamakido S, Takei S, Yokota S, Nishimoto T.
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomised controlled phase 3 TAKT study.

Rheumatology doi: 10.1093/rheumatology/kez630. Online ahead of print.

Yamagata K, Nakayamada S, Zhan T, Zhang X, Tanaka Y.
Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis.
Clin Exp Rheumatol 38, 670–679, 2020

Yamaguchi A, Hirata S, Kubo S, Fukuyo S, Hanami K, Nakano K, Nakayama S, Saito K, Tanaka Y.
5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
Mod Rheumatol doi: 10.1080/14397595.2019.1702141. Online ahead of print

Takeuchi T, Soen s, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, Tanaka Y.
Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE Modern Rheumatology.
Mod Rheumatol doi: 10.1080/14397595.2019.1703484. Online ahead of print

Tanaka Y, Kameda H, Saito K, Kaneko Y, Tanaka E, Yasuda S, Tamura N, Fujio K, Fujii T, Kojima T, Anzai T, Hamada C, Fujino Y, Matsuda S, Kohsaka H.
Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC Study.

Mod Rheumatol doi: 10.1080/14397595.2019.1709681. Online ahead of print.

Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T.
Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: A multicenter, randomized, comparative study.
J Bone Miner Metabolism 38, 511–521, 2020

Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, Itoh Y, Yasuoka H, Fukaya S, Ashihara K, Hirano D, Ohmura K, Tabuchi Y, Hasegawa H, Matsumiya R, Shirai Y, Ogura T, Tsuchida Y, Ogawa-Momohara M, Narazaki G, Inoue Y, Miyagawa I, Nakano K, Hirata S, Mori M.

2019 diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan Research Committee of the Ministry of Health, Labor, and Welfare for systemic autoimmune diseases.

Mod Rheumatol doi: 10.1080/14397595.2019.1709944. Online ahead of print

Zhang M, Iwata s, Hajime M, Ohkubo N, Todoroki Y, Miyata H, Ueno M, Hao H, Zhan T, Nakayamada S, Yamagaata K, Tanaka Y.

Methionine commits cells to differentiate into plasmablasts through epigenetic regulation of BTB and CNC homolog 2 by the methyltransferase enhancer of zeste homolog 2.

Arthritis Rheumatol 72, 1143–1153, 2020

Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, Othman A, Pangan A, Kitamura S, Meerwein S, Tanaka Y.

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase 2b/3 study.

Rheumatology doi: 10.1093/rheumatology/keaa084. Online ahead of print

Matsumoto, Yamamoto K. Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Matsumoto T.

Eldecalcitol is more effective than alfalcacitol in increasing bone mineral density in patients with glucocorticoid-induced osteoporosis: A multicenter, randomized, open-label study (e-GLORIA).

J Bone Miner Metabolism 38, 522–532, 2020

Takeuchi T, Tanaka Y, Higashitani C, Iwai M, Komatsu K, Akazawa R, Lademacher C.

A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate.

Mod Rheumatol doi: 10.1080/14397595.2020.1733214. Online ahead of print

Nakano K, Saito K, Nawata A, Hanami K, Kubo S, Miyagawa I, Fujino Y, Nakayamada S, Tanaka Y.

Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.

Mod Rheumatol doi: 10.1080/14397595.2020.1741870. Online ahead of print

Lee S, Nakayamada S, Kubo S, Yamagat K, Yoshinari H, Tanaka Y.

IL-23 drives expansion of Th17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients.

Tanaka Y, Soen S, Ishiguro N, Yamanaka H, Yoneda T, Tanaka S, Ohira T, Nitta T, Okubo N, Genant HK, van der Heijde D, Takeuchi T.

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.

RMD Open (2020) 6: e001249

Tanaka K, Okada Y, Hajime M, Mori H, Tanaka Y.

Associations between urinary 6-sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.

J Diabetes Invest (in press)

Smolen JS, Xie L, Jia B, Taylor PC, Burmester G, Tanaka Y, Elias A, Cardoso A, Ortmann R, Walls C, Dougados M.

Efficacy of baricitinib in patients with rheumatoid arthritis with three years of treatment: Results from a long-term study.

Rheumatology (in press)

Tokutsu A, Okada Y, Torimoto K, Tanaka Y.

Relationship between bloodinterstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; A pilot study.

Diabetology & Metabolic Syndrome (in press)

Johnson SR, Brinks R, Costenbader K, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Díaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Aringer M.

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.

Ann Rheum Dis (in press)

Miyagawa I, Tanaka Y.

Is precision medicine possible in rheumatic diseases? Selective use of targeted therapies in patients with psoriatic arthritis.

Expert Rev Clin Immunol. 2020; 16: 199–206

Tanaka Y.

State-of-the-art treatment of systemic lupus erythematosus.

Int J Rheum Dis (2020) 23, 465–471

Tanaka Y, Izutsu H.

Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.

Expert Opin Pharmacother. (2020) 21: 1015–1025

Tam L-S, Tanaka Y, Handa R, Chang C-C, Cheng YK, Isalm N, Li M, Lorenzo JP, Song Y-W, Yamamoto K, Zeng X, Haq SA.

Care for patients with rheumatic diseases during COVID-19 pandemic - a position statement from APLAR.

Int J Rheum Dis 23, 717–722, 2020

Miyagawa I, Tanaka Y.

The approach to precision medicine for the treatment of psoriatic arthritis.

Immunol Med doi: 10.1080/25785826.2020.1753430. Online ahead of print.

Tsujiimura S, Kawabe A, Tanaka Y.

P-glycoprotein expressing-B cell associated active true renal lupus vasculitis in lupus nephritis.

Lupus: Open Access (in press)

Yamagata K, Nakayamada S, Tanaka Y.

Critical roles of super-enhancers in the pathogenesis of autoimmune diseases.

Mod Rheumatol doi: 10.1080/14397595.2020.1782049. Online ahead of print.

Tanaka Y

A review of upadacitinib in rheumatoid arthritis.

Mod Rheumatol (in press)

Tanaka Y.

Rheumatoid arthritis.

Inflammation and Regeneration (in press)

Miyagawa I, Nakano K, Nakayamada S, Mori H, Okada Y, Saito K, Tanaka Y.

A case of systemic lupus erythematosus in which Cushing's syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids.

Mod Rheumatol Case Rep 4: 34–38, 2020

Miyagawa I, Kubo S, Tanaka Y.

A wide perspective of targeted therapies for precision medicine in autoimmune diseases.

Expert Review of Precision Medicine and Drug Development (in press)

Hao H, Nakayamada S, Yamagata K, Ohkubo N, Iwata S, Inoue Y, Zhang M, Zhang T, Satoh Kanda Y, Shan Y, Otsuka T, Tanaka Y.

IL-2 drives conversion of T follicular helper cells to T follicular regulatory cells through transcriptional regulation in systemic lupus erythematosus.

Arthritis Rheumatol doi: 10.1002/art.41457. Online ahead of print.

田中良哉

関節リウマチ患者におけるバリシチニブ治療による末梢血リンパ球サブセットの変化

リウマチ科 (2020) 63, 96–103

田中良哉.

関節リウマチの早期治療

CLINICIAN (2020) 678, 43–49

中山田真吾、田中良哉

SLE に対する濾胞性ヘルパーT 細胞の分化と機能

リウマチ科 (2020) 63, 176–183

中山田真吾、田中良哉

SLE における濾胞性ヘルパーT 細胞のエピゲノム制御

臨床免疫・アレルギー科 (2020) 73, 249–256

田中良哉

IgG4 関連疾患の治療

リウマチ科 (2020) 63, 305–312

田中良哉

ステロイド性骨粗鬆症の診断と治療

老年内科 (2020) 1, 444–452

中山田真吾、宮川一平、久保智史、田中良哉

末梢血リンパ球サブセットによる病態解析と臨床応用

Current Therapy (2020) 38, 467–472

田中良哉

JAK 阻害薬の最新研究:2 年間の関節破壊抑制効果からみた適正使用

Joint and Kinase Frontier (2020) 4, 2–7

中山田真吾、田中良哉
IgG4 関連疾患の末梢血リンパ球フェノタイプ
Current Therapy (2020) 38, 737

田中良哉、久保智史、井上嘉乃、中山田真吾
IgG4 関連疾患における免疫細胞とサイトカイン
炎症と免疫 (2020) 28, 304-309

岡田洋右、田中良哉
ステロイド性骨粗鬆症
糖尿病・内分泌代謝科 (2020) 51, 220-227

田中良哉
抗リウマチ薬と骨粗鬆症
糖尿病・内分泌代謝科 (2020) 51, 243-249

Kawabe A, Nakano K, Tanaka Y.
Focal eosinophilic myositis.
Internal Med (2020) 59, 141

Yamauchi Y, Nakano K, Miyagawa I, Inaba Y, Nawata A, Sato N, Kume S, Kawanami T, Yatera K, Tanaka Y.
An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because
of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma.
Mod Rheumatol Case Reports (2020) 4, 56-62

Funada M, Nakano K, Miyata H, Nawata A, Tanaka Y.
A case of IgG4 type multiple myeloma with diffuse enlargement of the thyroid requiring differentiation from
IgG4-related disease.
Internal Med (2020) 59, 711-714

Kurozumi A, Okada Y, Miyazaki Y, Nakayamada S, Tanaka Y.
Fulminant type 1 diabetes with diversity in peripheral blood lymphocytes: a case report.
J UOEH (2020) 42, 57-62

Nagayasu A, Nawata M, Saito K, Tanaka Y.
Short-term effectiveness of Ixekizumab to refractory psoriatic arthritis with spondyloarthritis: Two case
reports.
Mod Rheumatol Case Reports 4, 175-180, 2020

Hashimoto R, Katsuki A, Fujita Y, Ikenouchi A, Tanaka Y, Yoshimura R.

A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations.

Clinical Neuropsychopharmacology and Therapeutics (in press)

Funada M, Nakano K, Miyagawa I, Ueno M, Tanaka Y.

Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report.

Mod Rheumatol Case Reports 4, 229–232, 2020

Ueno M, Nakano K, Miyagawa I, Tanaka Y.

Five cases of IgG4-related diseases with nasal mucosa and sinus involvements.

Internal Med 59, 1905–1911, 2020

Kanda R, Nakano K, Miyagawa I, Iwata S, Nakayamada S, Tanaka Y.

A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumor necrosis factor- α (TNF- α) inhibitor, adalimumab.

Mod Rheumatol Case Reports 4, 196–201, 2020

Tokutsu A, Okada Y, Torimoto K, Otsuka T, Narisawa M, Kurozumi A, Tanaka Y.

Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases.

Neuroendocrinology Letters 27;41(1). Online ahead of print.

Kusaka K, Nakano K, Iwata S, Kubo S, Nishida T, Tanaka Y.

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators.

Mod Rheumatol Case Reports 4, 253–261, 2020

Kanda R, Kubo S, Nakano K, Kawabe A, Nawata A, Hanami K, Nakayamada S, Tanaka Y.

A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease.

Mod Rheumatol Case Reports 4, 278–282, 2020

Ohkubo N, Nakano K, Miyagawa I, Tanaka Y.

Mild encephalitis/encephalopathy with reversible splenial lesion in SLE.

Internal Med doi: 10.2169/internalmedicine.4612-20. Online ahead of print.

Koikawa K, Okada Y, Torimoto K, Tanaka Y.

A Case of Hyperparathyroidism Manifesting After Resection of a Fibroblast Growth Factor 23-producing Tumor.

Internal Med doi: 10.2169/internalmedicine.4412-19. Online ahead of print

Kurozumi A, Okada Y, Nishio K, Tanaka Y.

A case of autoimmune polyendocrine syndrome type 3 (APS-3) complicated by anti-N-methyl-D-aspartic acid-receptor (NMDA-R) encephalitis.

J Diabetes Invest doi: 10.1111/jdi.13341. Online ahead of print

Funada M, Nawata M, Nawata A, Miyamoto T, Saito K, Tanaka Y.

Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report.

Mod Rheumatol Case Reports doi: 10.1080/24725625.2020.1798061. Online ahead of print.

有富貴史、中野和久、吉成紘子、中山田真吾、岩田慈、福輿俊介、宮川一平、河邊明男、宮崎佑介、上野匡庸、田中良哉

強直性脊椎炎に対して TNF- α 阻害薬で加療中に発症した掌蹠膿疱症の 2 症例

九州リウマチ (2020) 40:62–69